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Abstract 
 
The DEAH helicase RHAU (alias DHX36, G4R1) was recently identified as a 
shuttle protein localized mainly in the nucleus. It is the only helicase shown to 
have G4-RNA resolvase activity and the major source of G4-DNA resolvase 
activity in HeLa cell lysate. Its ablation reduces the proliferation rate of various 
human cell lines in culture. The Human Gene Atlas database (GNF, Novartis) 
shows ubiquitous expression of RHAU, with prominently elevated levels in 
lymphoid and CD34+ bone marrow cells, suggesting a potential role in 
hematopoiesis. To investigate the biological role of RHAU, we generated mice in 
which the RHAU gene was targeted conventionally or specifically in the 
hematopoietic system.  
 
Conventional RHAU ablation caused embryonic lethality before 7.5 days after 
fertilization but without disturbing embryo implantation, suggesting a 
fundamental role for RHAU in early development (gastrulation).  
 
Because conventional RHAU-ablation caused embryonic lethality, we then 
targeted the RHAU gene specifically in the hematopoiesis system. To achieve this 
we used vav1-iCre system, in which iCre gene (an optimized variant of Cre 
recombinase) was expressed under the control of vav1 oncogen promoter that was 
active solely in the hematopoietic system. Results showed that RHAU-ablation in 
the hematopoietic system strongly affected the process of hematopoiesis in a 
lineage- and stage-specific manner. Notably, RHAU ablation caused hemolytic 
anemia and strong impairment of lymphoid cell differentiation at early its stages.  
 
Finally, by micro-array analysis we examined the effect of RHAU ablation on the 
change of transcriptome in proerythroblasts. We found that within a group of 
genes involved in cell death and cell cycle regulation, RHAU-ablation 
deregulated those genes that contained G-quadruplex motifs in their promoter 
regions.  This result suggests that RHAU plays a role in the regulation of gene 
expression through involving its G4 resolvase activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE OF CONTENT 
1 Introduction .........................................................................................................1 
1.1 RNA helicases .....................................................................................................1 
1.2 Evolution and RNA helicases..............................................................................1 
1.3 The structure of RNA helicases...........................................................................2 
1.4 The mechanism of RNA helicase ........................................................................5 
1.5 Biological functions of RNA Helicases...............................................................6 
1.5.1 RNA helicase in RNPase remodeling..........................................................7 
1.5.2 DExH/D Helicases in transcription .............................................................8 
1.5.3 DExH/D Helicases in splicing.....................................................................9 
1.5.4 DExH/D RNA helicases in mRNA turnover...............................................9 
1.5.5 RNA Helicase in translation ......................................................................10 
1.5.6 RNA helicases are essential for embryogenesis and 
differentiation ............................................................................................12 
1.5.7 RNA helicases in hematopoiesis ...............................................................13 
1.5.8 The role of RNA helicases in cancer .........................................................13 
1.6 The RHAU gene ................................................................................................14 
1.6.1 RHAU promotes exosome-associated mRNA decay ................................17 
1.6.2 RHAU resolves RNA and DNA tetramolecular quadruplexes .................17 
1.6.3 RHAU localized to stress granules (SGs)..................................................18 
1.6.4 RHAU is a nuclear protein ........................................................................18 
1.7 Hematopoiesis ...................................................................................................20 
1.7.1 Hematopoietic cells ...................................................................................20 
1.7.2 Origin of hematopoiesis in mouse .............................................................23 
1.7.3 Differentiation road of hematopoietic cells in adult mice .........................24 
2 Materials and Methods ......................................................................................32 
2.1 Generation of RHAU-targeted mice..................................................................32 
2.2 Genotyping ........................................................................................................33 
2.3 Analysis of the efficiency of implantation ........................................................34 
2.4 Western blot analysis.........................................................................................34 
2.5 Histology ...........................................................................................................34 
2.6 Complete blood count analysis..........................................................................35 
2.7 FACS analysis ...................................................................................................35 
2.8 Bone marrow transplantation.............................................................................35 
2.9 Colony forming assay........................................................................................36 
2.10 Determination of the half lives of erythrocytes by in vivo biotin 
labeling ..............................................................................................................36 
2.11 Determination of the half lives of erythrocytes by in vitro biotin 
labeling ..............................................................................................................36 
2.12 Determination of the osmotic resistance ...........................................................37 
2.13 Quantization of plasma concentrations of erythropoietin..................................37 
2.14 Annexin V staining of erythrocytes...................................................................37 
2.15 mRNA microarray analysis ...............................................................................37 
3 Results ...............................................................................................................39 
3.1 Comparison of the primary structure of human and mouse RHAU..................39 
3.2 RHAU protein is ubiquitously expressed in adult mouse..................................40 
  
3.3 Generation of RHAU-targeted mice..................................................................41 
3.4 Loss of RHAU caused embryonic lethality but had no effect on the 
implantation efficiency......................................................................................43 
3.5 Conditional knockout of RHAU in hematopoietic system causes 
anemia................................................................................................................45 
3.6 Effects of RHAU knockout on different lineages in peripheral 
blood ..................................................................................................................47 
3.7 FACS analysis of different hematopoietic cell lineages in spleen, 
bone marrow and thymus ..................................................................................51 
3.7.1 Loss of RHAU leads to erythropoiesis defect ...........................................51 
3.7.2 Loss of RHAU leads to changes in granulocyte and lymphoid 
cell numbers...............................................................................................53 
3.7.3 Characterization of hematopoietic progenitors in RHAU-
ablation mice showed a shift of progenitor and stem cell 
populations.................................................................................................58 
3.7.4 Loss of RHAU leads to progressive reduction of population 
expansion ability in hematopoietic stem cells and 
erythroblasts...............................................................................................61 
3.7.5 In vitro colony forming assay....................................................................65 
3.7.6 Quantization of plasma concentrations of erythropoietin..........................67 
3.7.7 Blood smear examination showed spherocytosis in the 
RHAUfl/fl; iCretg mice ................................................................................68 
3.7.8 Determination of the osmotic resistance ...................................................69 
3.7.9 Chasing of biotinylated erythrocytes revealed shortening of 
half lives of erythrocytes in RHAU knockout condition...........................71 
3.7.10 Comparison of ProE transcriptomes of RHAUfl/fl control mice 
and RHAUfl/fl; iCretg mice revealed an enrichment of genes 
with G-quadruplexe motifs at their promoters ..........................................73 
4 DISCUSSION....................................................................................................79 
4.1 RHAU is required for mouse early embryogenesis...........................................79 
4.2 RNA helicases in hematopoiesis .......................................................................79 
4.3 Loss of RHAU causes anemia, low blood platelet counts and 
leucopenia..........................................................................................................80 
4.4 Lineage-specific effect of RHAU ablation on lymphoid cell 
differentiation ....................................................................................................81 
4.5 Specific potentiation of monocytes differentiation by RHAU 
ablation ..............................................................................................................82 
4.6 Study of transcriptome in RHAU knockout ProE showed 
enrichment of genes that contained putative G-quadruplex (G4) 
motifs in their promoters ...................................................................................82 
4.7 Hemolytic anemia in RHAUfl/fl; iCretg mice .....................................................83 
4.8 Potential target against leukemia.......................................................................85 
5 Reference ...........................................................................................................87 
APPENDIX I: Antibody list for FACS analysis ...............................................................98 
APPENDIX II: List of genes that are deregulated in ProE when RHAU is 
knockout .........................................................................................................................101 
Abbreviation 
Acknowledgements 
  
1 Introduction 
 
RNAs are an important group of molecules for gene regulation in organisms. 
From transcription to signaling, RNA molecules can be found playing roles in all 
aspects. The biological roles of RNA molecules were extensively investigated in 
the last few decades. Since the discovery of siRNA in the early 90s of the last 
century, more people started to realize the important role of RNA metabolism in 
cell development and survival. In recent years, there is a huge increase of studies 
concerning the role of RNA binding molecules that directly regulate the RNA 
metabolisms. However, there is still numerous of proteins that regulate RNA 
metabolism but have never been looked at. Here, I am going to present a study 
using knockout mice model in which an RNA helicase, RHAU, is targeted I wish 
that this mouse model can also give some hints of how the other DEAH helicases 
function in mammals.  
 
The biological function and the mechanism of RHAU are still almost unknown. 
In order to start to investigate this new protein, the best way is to get some 
information from other helicases. Here, I will guide you to know more about 
helicase, how the helicase structure is related to its function and biology of 
helicases.  
 
1.1 RNA helicases 
 
RNA helicases are proteins with enzymatic activity. They associate with RNA 
molecules and regulate various aspects of RNA metabolism. They can resolve 
complex RNA structures and displace proteins from RNA-protein complex with 
or without the hydrolysis of nucleoside triphosphates (Hilbert et al., 2009). 
Usually RNA helicases share conserved core domains. These core domains are 
critical for RNA binding and NTP hydrolysis. Each RNA helicase evolved with 
unique C and N termini that contribute to its specific functions (Jankowsky and 
Fairman, 2007). Although helicases are ancient molecules like RNA polymerase, 
the knowledge we have is too little compare to the level of importance of these 
protein in life.  
 
1.2 Evolution and RNA helicases 
 
RNA helicase was evolved in the necessity of resolving complex RNAstructures. 
Correct folding of RNA molecules in secondary, tertiary and quaternary 
structures is critical for their proper functions in transcription, splicing, processing 
and editing of transcripts, translation, RNA degradation and its regulation 
(Herschlag, 1995) (Anantharaman et al., 2002). According to a comparative 
genomics and protein evolution study on RNA metabolism carried by 
Anantharaman and his colleagues and published in 2002, around 3 to 11% of the 
complete proteome are related to RNA metabolism in bacteria, archaea and 
eukaryotes. Interestingly, half of these RNA metabolism-related domains are 
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shared amongst all three bacterial, archaeal and eukaryotic kingdom. These 
protein domains are even traceable to the last universal common ancestor from 
which all organisms on Earth descended (Anantharaman et al., 2002) (Doolittle, 
2000) (Glansdorff et al., 2008). Amongst these RNA metabolism related proteins, 
RNA helicases form the largest group.  
1.3 The structure of RNA helicases 
 
The name “Helicases” was initially used to descript the proteins that harbor the 
catalytic activity of separating duplex DNA or RNA into two single strands in an 
ATP-dependent reaction. These helicases were grouped into two types based on 
the mode of activity, (1) unwinding duplexes in a 3’ to 5’ direction and (2) 
unwinding 5’ to 3’ direction (Caruthers and McKay, 2002). All of the helicases 
carry the classical Walker ‘A’ (phosphate-binding loop or ‘P-loop’) and Walker 
‘B’ (Mg2+-binding aspartic acid) motifs (Walker et al., 1982). Later in 1993, 
Gorbalenya and Koonin proposed to divide helicases into five major groups based 
on the conserved motifs or signatures found in the core catalytic domains. These 
groups are superfamily (SF) I, II and III, DnaB like family and Rho-like family 
(Gorbalenya and Koonin, 1993). SF1 includes some RNA helicases; 
superfamilies 2 (SF2) contributes the largest size of the helicase population; SF3 
and SF4 include some viral RNA helicases.  
 
SF2 include DNA and RNA helicases from the three primary kingdoms and 
viruses. They unwind nucleic acids in either directions of nucleic acid duplex 
(Caruthers and McKay, 2002). With the increasing knowledge of helicases, some 
SF2 helicases were found to remodel nucleic acid structures rather than unwind 
nucleic acid duplex (Staley and Guthrie, 1998). Based on the homology of 
primary structure of the helicases, SF2 are divided into DExH/D, the RecQ and 
SWI/SNF families. DExH/D proteins are further divided into DEAD-box, DExH 
and DEAH subfamilies (Jankowsky and Fairman, 2007). In mammals, DEAD-
box proteins were assigned with gene symbol of DDX-, where DEAH or DExH 
proteins were assigned with DHX- (Abdelhaleem et al., 2003). For example, 
RHAU share the maximum homology with a series of DEAH RNA helicase in 
SF2, and this protein was assigned with DHX36 symbol even though it contains 
DEIH amino acid sequence rather than DEAH (Figure 1.1 and Figure 1.2A).  
 
A total of at least eight motifs, motif I, Ia, Ib, II, III, IV, V and VI, were identified 
from the SF2 helicases (Figure 1.2.A). Motifs I and II are the classical Walker A 
and B, respectively. These eight motifs distribute on two helicase core domains (1 
and 2) which are connected via a flexible linker region. This special structure is 
named RecA-like helicase domains which are involved in an ATP hydrolysis and 
nucleic-acid binding (Figure 1.2.B). Motifs Ia, Ib, Ic, IV and IVa locate at the 
surface of the helicase domains where it contacts the nucleic acid backbone. In 
the inner side of the cleft between the two helicase domains, motifs I, II and VI 
bind to nucleic acids while motifs III and V coordinate polynucleotide binding 
and ATPase activity. When SF2 helicases are bound to ATP, the two RecA 
domains transform from an open confirmation to a closed conformation.  
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Figure 1.1. Alignment of the amino acid sequences of mammalian DEAH helicases. RHAU (DHX36) gene is 
in the human protein group. The dark and light green boxes represent the RecA domains 1 and 2 (Helicase 
core domain). Strips in the domains represent consevered motifs I to VI in the helicase core domain across all 
SF1 and SF2 helicases. Dodgerblud boxes are winged-helix domain (WHD), lightskyblue boxes are Ratchet 
domain, and navyblue boxes are oligonucleotide/oligosaccharide-binding fold (OB-fold) domain. The 
alignment shows that all the members share specific WHD, Ratchet and OB domains (unpublished data from 
Simon Lattmann, 2007).  
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Figure 1.2. (A) Summary of sequence characteristics found in SF2 helicases. The tree diagram (left) shows 
the phylogenetic relationship of SF2 subfamilies helicases. Helicase domains are represented as dark gray 
blocks, and C and N termini are in light gray blocks. Insertions in the helicase domains are labeled. The 
blocks are not to scale in length. Colored blocks represent conserved functional motifs: red, ATP binding and 
hydrolysis; yellow, coordination between polynucleotide binding and ATPase activity; blue, nucleic acid 
binding. The DExH/D group helicases includes DEAD-box, DExH and DEAH subgroups. B (Left) The 
topology of the two RecA-like helicase domains. Solid outlined elements are presented in all SF2 helicases 
and dashed outlined elements are not present in all proteins. The position of the conserved sequence motifs is 
indicated by numbered octagons, colored as in (A). (B)   The structure of the SF2 helicase DEAD-box 
protein VASA with bound ATP analog (black) (Sengoku et al., 2006). Conserved sequence motifs are 
colored as in (A) [Figure is modified from  (Jankowsky and Fairman, 2007)]. The updated gene list of SF2 
family is available on line http://www.dexhd.org/index.htm 
 
 
Most of knowledge of RNA helicase structure are derived from  studies on SF2 
DEAD-box helicases (Andersen et al., 2006; Mackintosh et al., 2006) (Kim et al., 
1998) (Bono et al., 2006; Sengoku et al., 2006). The mechanism of ATP 
hydrolysis is different among different helicases even though all SF2 helicases 
have the ATP binding and hydrolysis site in the core domain;  DEAD-box 
helicase require nucleic acid to hydrolyze ATP while DEAH helicases can 
hydrolyze ATP in the absence of nucleic acid (Talavera and De La Cruz, 2005) 
(Iost et al., 1999) (Lorsch and Herschlag, 1998) (Polach and Uhlenbeck, 2002). 
Only last February, the first paper about the crystal structure of a DEAH helicase, 
Prp43p from yeast, appeared (He et al., 2010). This exciting data provides a bit 
more structural information of DEAH helicases outside the core RecA domains 
for the first time. Prp43p is a yeast homolog of mammalian DHX15 that is 
involved in per-messenger RNA splicing and pre-ribosomal RNA processing in 
yeast (Tanaka et al., 2007). This study has demonstrated that the structural 
building blocks in Prp43p are also represented in other DEAH helicases (Figure 
1.1). Like DEAD-box helicases, DEAH helicases contain two RecA domains. 
Surprisingly, the sequence outside the core domains of these DEAH helicases 
share high homology with that of Hel308 and Hjm DNA helicases. In this region, 
there is a degenerated winged-helix domain (WHD) with a weakly defined β-
sheet followed by a ratchet domain and then a C-terminal domain (CTD). The 
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CTD shows a structural homology to eIF1A. The WHD, ratchet domain and CTD 
all contact with the amino-terminal domain. The hairpin 5’HP, extending from the 
motifs V and VI of RecA2, is inserted into a cleft between the WHD and CTD 
(Figure 1.3). This hairpin is close to the 5’end of the putative binding pocket for 
ssRNA in the ATP state. Similar to the Hel308, this helix may be used to unwind 
very stable nucleic acid duplex (Zhang et al., 2009) (Pena et al., 2009) (He et al., 
2010). Though we have some knowledge about the DEAH helicase structure by 
looking at this Prp43p protein, the N-terminus of RHAU is very unique not only 
among all DEAH helicases but any other proteins with known structural 
information. In order to know how RHAU function in the cell, elucidation of the 
crystal structure of this region is particularly critical.  
RecA-2
3R
Ratchet Ratchet
ADP
5′HP
CTD
CTD
NTD NTD
WHD
WHD
ADP
RecA-1
RecA-2
RecA-1
   
Figure 1.3. The structure of Prp43p. The extended NTD region is coloured blue, 
RecA domain 1 green, RecA domain 2 magenta, the 5’HP yellow, the WHD 
orange, the ratchet domain cyan and the CTD red. 3R is a long helix with the 
ratchet domain involved in RNA interaction [figure is modified from (He et al., 
2010)].  
 
1.4 The mechanism of RNA helicase 
 
Based on the available biochemistry analysis, we knew that some RNA helicases 
firstly bind to a single stranded over-hanged nucleic acid and then slide along the 
RNA strands. Take Helicases nucleoside triphosphate phosphohydrolase II (NPH-
II) and NS3 from viruses as examples. They just slide along one of the strands of 
the RNA duplex in an ATP dependent activity rather than binding on both strands 
(Kawaoka et al., 2004) (Beran et al., 2006). To explain how the helicase move 
along the nucleic acid strand, three models were widely proposed. They are (1) 
active rolling mechanism, (2) inchworm mechanism and (3) Brownian motor 
model (Figure 1.4). In rolling mechanism hypothesis, helicases work as a dimer 
with different conformation, one is opened when the next one is closed. Some 
helicases bind at a single stranded nucleic acid and others bind double stranded 
regions. The conformation of the monomer is changed for every single step when 
sliding along the RNA strands. For the inchworm model, helicases work as 
monomers. In this model, the helicase opens and closes the RecA domain 1 and 2 
and slide along the nucleic acid strands. This movement is coupled with NTP 
hydrolysis (Tanner and Linder, 2001). In the Brownian motor model, NTP 
hydrolysis at the helicase core domain leads to change of protein conformation. 
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The change of conformation also leads to changes in nucleic acid binding 
affinitys by the helicase. When the helicase bind on the nucleic acid tightly, the 
helicase cannot move along the nucleic acid strand. When the helicase becomes 
loosened, it can move along the nucleic acid chain (Bleichert and Baserga, 2007).  
nucleic acid length
dissociate from
nucleic acid
 
 
Figure 1.4. Three different models for helicase activity. (Top) Active rolling model. Each hand represents 
one helicase. The orientation of the hand does not represent the orientation of the helicase here. (Middle)  
Ichworm mechanismand. The anterior and posterior end of a worm represents the RecA domain 1 and 
domain 2. (Bottom) Brownian motor model. Image on the right shows a helicase undergoing nucleic acid 
affinity changes. (1) the helicase is the original position, (2)  the helicase which, with an affinity to the 
nucleic acid is in a weak state, is fluctuating in either directions, (3) the helicase,  resumed the original 
conformation, either moves forward or returns to the pervious place, (4) the helicase detaches from the 
nucleic acid. Graph on the left showes the energy change for tightly and loosely bound states. E on the x-axis 
is the energy state, whereas y-axis is the nucleic acid length. The underlying mechanisms were described in 
the text. (Figures were modified from (Tanner and Linder, 2001) and (Patel and Donmez, 2006) )  
 
1.5 Biological functions of RNA Helicases 
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DExH/D helicases are found in all aspects of RNA metabolism. In addition, one 
RNA helicase may have more than one function in a cell. It is very common that 
an RNA helicase originally found in mRNA splicing may also be involve in other 
pathways like mRNA decay. This interesting feature of helicases can be explained 
as follows. RNA metabolisms always involve large groups of proteins working 
together. Different steps of reactions will need different protein components in the 
complexes. The composition of the complexes rather than individual protein 
determines the function of the complexes. Therefore, one RNA helicase can be 
found in several different complexes in different regions of a cell for different 
functions.  
 
1.5.1 RNA helicase in RNPase remodeling 
 
RNA molecules will automatically form a structure of the lowest energy state. 
Improper folding of the RNA molecules will disrupt RNA metabolism including 
mRNA splicing, mRNA translation and RNA interference. DExH/D helicases are 
the proteins that remodel complicated RNA structures or RNA-protein complexes. 
Once RNAs are transcribeed, they form into complexes with other proteins called 
ribonucleoprotein complexes (RNPs). Since RNA needs to be handled differently 
at different sites, the compositions of RNPs are changing all the time as well. 
Correct composition of the RNPs and RNA folding at specific time and places are 
critical for specific functions. The composition of RNPs is dynamic and these 
dynamic processes are mediated by remodeling activity of various RNPases, 
DExH/D helicases being part of them.  
 
The first model showing the ability of a DExH/D helicase to displace protein off 
from RNPs was reported in 2001 (Jankowsky et al., 2001). In this study, the 
DExH/D protein nucleoside triphosphate phosphohydrolase II (NPHII) from 
vaccinia virus could actively displace the U1 small nuclear ribonucleoprotein A 
(U1A), part of the pre-mRNA splicing machinery, in an ATP-dependent manner 
from a single strand overhang U1A binding site substrate. In this case, the RNA 
duplex unwinding and displacement happened concurrently. Later in 2004, 
another two models were proposed to showing that unwinding activity of an RNA 
helicase was not essential for the displacement of protein from RNPs by DExH/D 
helicase. Tryptophan RNA-binding attenuation protein (TRAP) formed a RNP 
with its specific 53-nt-long cognate RNA substrate in which secondary structure 
played no role for the RNP formation. NPH-II readily displaced TRAP from the 
RNA containing the single-stranded extension in an ATP-dependent way. 
Furthermore, another model using exon junction complex (EJC) with an RNA 
substrate, of which single-stranded regions being adjacent to the EJC-binding site, 
showed that two helicase NPH-II and DED1 were able to displace EJC from the 
RNA substrates. These studies also revealed that RNPase activity is substrate 
dependent; DED1 could not displace TRAP from the RNA substrate (Fairman et 
al., 2004). Although DExH/D RNA helicases have RNPase activities, the 
underlying molecular mechanisms still remain to be elucidated.  
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1.5.2 DExH/D Helicases in transcription  
 
RNA helicases play a role in transcription. The most classic example of DEAH 
helicase being involved in transcription is the Drosophila maleless (Mle) protein 
encoded by MLE gene (Kuroda et al., 1991). Mle gene was found in Mle mutant 
Drosophila. Male Mle mutant are lethal and the female are viable. In Drosophila, 
the males have one X chromosome and one Y chromosome. Female have two X 
chromosomes. Since the male flies have one X chromosome less compared to 
their female counterparts, most genes on X chromosome in the male are needed to 
be transcribed 100% more efficient than that in female in order to compensate the 
gene dosages. This enhanced transcription activity is regulated by dosage 
compensation complex (DCC). DCC is composed of male-specific lethal-
1(MSL1), male-specific lethal-2(MSL2), maleless on the third-132 (MSL3), 
maleless (MLE), male-absent-on-the-first (MOF) and two noncoding roX RNAs. 
The complex acetylates histone H4 at lysine 16 (H4K16ac) and leads to active 
transcription (Kotlikova et al., 2006). Mle protein and other components of the 
DCC were found associating along the whole X chromosome and mainly 
localized in actively transcribed regions in male Drosophila in an RNA dependent 
manner (Kotlikova et al., 2006) (Richter et al., 1996).  
 
Mammalian DHX9 [also called RNA helicase A (RHA) or nuclear DNA helicase 
II (NDHII)] is an ortholog of Mle (Lee et al., 1997; Lee et al., 1998; Lee and 
Hurwitz, 1992; Zhang et al., 1995). Since the dosage compensation mechanisms 
for X chromosome in mammals is different from that in Drosophila, the above 
described case may not applicable in mammals. However, mammalian DHX9 has 
been shown to activate some transcription. It was reported that DHX9 acts as a 
bridging factor between the cAMP response element-binding, CREB-binding 
protein (CBP) and PolII. The N-terminal domain of DHX9 interacts with PolII 
independent of ATP activity but the CBP-dependent transcription is dependent on 
ATPase activity (Aratani et al., 2001). DHX9 also bridges the breast cancer-
specific tumor suppressor (BRCA1) and PolII holoenzyme (Anderson et al., 
1998). The interactions of DHX9 with other transcription factors like NF-kappaB 
and p16Ink4a were reported as well (Myohanen and Baylin, 2001) (Tetsuka et al., 
2004).  
 
DEAD-box helicases DDX5 (p68) and DDX17 (p72) were frequently found 
working as a dimer, and both proteins were found interacting with RHAU 
(Iwamoto, 2007). There are reports showing the involvement of the p68-p72 
complex in transcription activation. It acts as transcription initiation components 
by bridging PolII and coactivators CBP/p300 (Rossow and Janknecht, 2003), 
interacts with a transcriptional activator Smad3, is localized at the ERα promoter 
upon estrogen treatment, acts as a coactivator of p53 and acts on p53 targeted 
promoter leading to gene expression enhancement in response to p53 pathway 
dependent stress response. Though p68 and p72 were initially reported as 
transcription activators, they also can repress transcription through the interaction 
with Histone deacetylase 1 (HDAC1).  
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1.5.3 DExH/D Helicases in splicing 
 
In eukaryotic cells, pre-mRNA is processed by splicing factors once it is 
transcribed by DNA dependent RNA polymerases (Das et al., 2006). It is not 
surprise if an RNA helicase participates both in transcription and splicing at the 
same time. For example, DHX9 is associated with survival motor neuron protein 
(SMN) in nuclear Gem bodies and cytosolic spliceosomal small nuclear 
ribonucleoprotein complexes  (Pellizzoni et al., 2001). The p68-p72 complex was 
found to be part of the spliceosomes. p68 alone acts as a splicing protein and acts 
at the U1 snRNA-5’ site. p72 alone ws co-purified with U1 snRNP(Neubauer et 
al., 1998). In addition, the p62-p72 complex is known to be essential for 
alternative splicing of H-ras and CD44 (Fuller-Pace, 2006).  
  
1.5.4 DExH/D RNA helicases in mRNA turnover 
 
Regulation of RNA turnover is essential for cellular survival, because it plays an 
important role in gene expression, defense against virus infection and prevention 
of transposons RNA expression. These processes are highly regulated and involve 
a wide range of proteins. Many of these proteins are conserved across organisms 
(Meyer et al., 2004) (Coller and Parker, 2004) (Table 1.1). The half lives of 
mammalian mRNA range from 15 minutes to 50 hours (Stolle and Benz, 1988) 
(Shyu et al., 1989). Although cells are using the same basic machineries 
fordegradation of for different mRNAs, different mRNAs have different half lives 
in the same cell. This implies that each mRNA is regulated in a specific manner. 
Cells should be able to distinguish between mRNAs for degradation. In 
eukaryotic cells, the 5’ m7GpppN cap and a 3’poly(A) tail on an mRNA protect it 
from undergoing decay. When the mRNAs are ready to be processed for decay, 
majority of mRNAs undergo deadenylation-dependent decapping pathway. Under 
this pathway, mRNAs first undergo the removal of the poly(A) tails and followed 
with hydrolysis of the 5’cap to give a 5’monophosate-mRNA. The decapped 
mRNA is then either degraded by a 5’exonuclease, 3’ exonuclease or 
endonuclease (Meyer et al., 2004).  
 
Table 1.1  A summary of the proteins participating mRNA decay with 5’ or 3’ exonucleolytic activity of 
eukaryotic cells. Activators and inhibitors of the mRNA decay were labeled as effectors (Meyer et al., 2004).  
 9 
 
 
 
 
DExH/D helicases have been found as the components of the basic machineries of 
RNA decay (Table 1.1). Dhh1 is a DEAD-box protein in yeast. It is a decapping 
activator and translation repressor. It converts mRNA from translation-active state 
in the cytoplasm to a non-active state  the P-bodies(Coller and Parker, 2004).  
 
Furthermore, there are pathways to remove aberrant mRNA produced by splicing 
errors. Nonsense-mediated decay (NMD) and nonstop decay are pathways to 
eliminate mRNAs that have a premature stop codon and lack a stop codon, 
respectively   (Frischmeyer et al., 2002; Van Hoof, 2001). DNA rearrangements 
in B and T cells during maturation, nonsense mutations and splicing errors can 
produce harmful C-terminal truncated proteins. In mammals, NMD depends on 
the splicing activity. When a termination codon appears at the upstream of an 
exon with <50 to 55 nt away, it becomes a premature termination codon and 
triggers NMD. During translation, the ribosome scans along the mRNA and 
removes exon junction complexes (ECJ) that are formed during splicing in the 
nucleus. When a premature termination codon appears, ribosome is stopped and 
leaves the EJC unremoved at the downstream. This EJC becomes a platform for 
the recruitment of NMD machinery and starts mRNA decay. The human NMD 
involves UPF1, UPF2, UPF3, UPF3B, SMG1, SMG5, SMG6, SMG8, SMG9, 
NAG and DHX34(Nicholson et al.). DHX34 is a DEAH helicase and was 
recently identified as part of NMD in C. elegans (Longman et al., 2007). It was 
found that DHX34 was highly conserved in C. elegans and human. Knocking 
down of DHX34 in either C. elegans or human cells reversed NMD activity 
(Longman et al., 2007).  
 
 
1.5.5 RNA Helicase in translation 
 
Translation initiation is the slowest step in eukaryotic translation. When 
translation starts, a 40S ribosomal subunit forms an initiation complex with eIFs 1 
and 1A, 2 and 3. This complex then is charged with a ternary tRNAMet complex 
(tRNAMet/eIF2/GFP) to form a 43S initiation complex. This initiation complex is 
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directed to the 5’untranslated region (5’UTR) of mRNA and scans for the start 
codon. It becomes a 48S complex when it meets the start codon. The mRNAs in 
eukaryotic cells usually are capped with m7G5’ppp5N structure at the 5’ end in 
addition to a relatively unstructured 5’UTR less than 100 nucleotides. The landing 
of 43S ribosomes initiation complex on the mRNAs requires eIF4F, 4A and 4B. 
The eIF4F is composed of eIF4E, eIF4G and eIF4A. eIF4E recognizes the 5’ cap 
of mRNAs. eIF4G is a scaffolding protein associate with eIF4E and eIF4A and 
eIF3. eIF4A is a DEAD-box helicase (Figure 1.5). Mammalian DDX3 and its 
yeast homologue DED1 were also found manipulating the translation efficiency.  
 
 
   
 
Figure 1.5. Overview of the translation initiation process in eukaryotic cells. 4E-BP is eIF4E-binding protein. 
(Figure was modified from (Linder, 2003)).  
 
The binding affinity of regulatory proteins at the 5’UTR can be modulatedby 
changing the tertiary structure of mRNA, leading to changes in translation 
efficiency (Linder, 2003) (Baim and Sherman, 1988; Pelletier and Sonenberg, 
1985). As mRNA structure takes part in the translation initiation regulation, 
helicases become important for gene expression regulation. However, the 
characterization of how helicases are involved in translational control has not 
been fully studied.  
 
Some retroviruses pre-mRNA and some mammalian mRNAs from intronless 
genes contain highly structured and long 5’UTR. In these cases 5’UTR takes part 
in the translation initiation control (Short and Pfarr, 2002). These highly 
structured 5’UTRs that harbor translation initiation regulating function are called 
5’-terminal post-transcriptional control elements (PCEs) and are present in 
several viral and human genes. It was published for the first time in 2006 
(Hartman et al., 2006) that the DEAH helicase DHX9 was necessary for efficient 
translation of mRNA with PCE. The DHX9-PEC interaction is sequence specific 
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and enhances the polyribosome assembly and protein synthesis. Another DEAH 
helicase, DHX29, was shown to be important for translation initiation beside 
DHX9. DHX29 was shown to bind to 40S monomers and dimmers. Though the 
detailed mechanism is still unknown, this protein might directly unwind mRNA 
before loading of 40S initiation complex on the mRNA or remodeling the 43S 
complexes.  
 
 
1.5.6 RNA helicases are essential for embryogenesis and 
differentiation 
 
Differentiation is a process that involves continuous global changes of gene 
expression. Modulation of RNA metabolism is critical for proper differentiation. 
Distortions of the expression of RNA helicases have been demonstrated in 
knockout mouse models. Several RNA helicases are specifically expressed in 
germ cells and embryos. Analysis of global gene expression patterns suggests that 
these RNA helicases play roles in differentiation and embryogenesis. A few RNA 
helicases have been knocked out in mice. I will briefly describe three such cases 
in which the knocked out RNA helicases are related to RHAU and involved in 
embryogenesis.  
  
DEAD-box helicases p68 and p72 are structurally closely related protein, being 
members of the same SF2 family, and are co-immunopreciptated with RHAU in 
HeLa cells (Iwamoto, 2007). Expression of these helicases was shown to be 
developmentally regulated (Stevenson et al., 1998), and later they were found to 
be involved in pre-mRNA processing (Lee, 2002; Liu, 2002). These two helicases 
showed specific expression pattern during muscle and adipocyte differentiation 
(Caretti et al., 2006) (Kitamura et al., 2001). As described before, p68, p72 form a 
complex with a noncoding RNA, SRA. It was reported that this p68-p72-SRA 
complex was essential for the activation of Myo D transcriptional factor and also  
for the formation of the transcription initiation complex and chromatin 
remodeling (Caretti et al., 2006). Konckdown of p68 and p72 in vitro led to 
differentiation defect in myoblasts (Caretti et al., 2006). p68 single gene knockout 
mice were embryonic lethal at around 11.5 dpc. p72 single gene knockout mice 
caused neonatal death at day 2 after birth. p68-p72 double knockout mice resulted 
in earlier lethality at least before 8.0 dpc (a stage before organogenesis start). The  
lethality of p68-p72 knockout mice compare to single gene knockout mice 
implied that functions of these two genes are partially but not totally redundant 
(Fukuda et al., 2007; Uhlmann-Schiffler et al., 2006).  
 
DHX9 is able to bind and catalyze the unwiding of both DNA and RNA. It 
involves in transcription regulation (Nakajima et al., 1997), mRNA processing 
(Zhang et al., 1999), translation initiation (Bolinger et al., 2010) and RNA editing 
(Reenan et al., 2000). DHX9 ablated mice are lethal at 7.5 dpc. This model 
showed that DHX9 was not essential for gastrulation initaiton. It was because 
DHX9-ablated embryos showed some signatures of gastrulation initiation such as 
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the present of extraembryonic, yolk sac and structure with blood island markers 
(Lee et al., 1998).  
 
 
1.5.7 RNA helicases in hematopoiesis 
 
So far, only one member of the DEAH RNA helicase family has been suggested 
to play a role in hematopoiesis. Ubiquitously expressed DHX32 was found to be 
specifically downregulated in acute lymphoblastic leukemia (Abdelhaleem, 2002), 
possibly through suppressing apoptosis (Alli et al., 2007). A causal role for this 
helicase in leukemia development, however, has not yet been addressed. 
  
 
1.5.8 The role of RNA helicases in cancer 
 
Since RNA helicases regulate RNA metabolism, deregulation of these proteins 
could result in distortion of the downstream RNA processing and lead to global 
changes of cellular activity. Several RNA helicases were reported to be 
overexpressed in cancer as a result of chromosome aberration (Abdelhaleem, 
2004). Some of them are shown to be co-immunoprecipitated with RHAU, such 
as DDX1 (Iwamoto, 2007), p68 (Iwamoto, 2007) and DHX9 (unpublished data).  
 
It was reported that DDX1 gene was co-amplified with MYCN in neuroblastoma 
(Godbout et al., 1998) (Pandita et al., 1997) (Squire et al., 1995) (Manohar et al., 
1995). MCYN is a member of the myc family and is a biomarker for poor 
prognosis of neuroblastoma (Schmidt et al., 1994). Although not all MCYN 
overexpressing tumors show co-amplification of DDX1, tumors with both genes 
amplifiedare usually of higher grade. DDX1 is known to be a nuclear protein 
which involves pre-mRNA processing at the 3’-end and interacts with the 
nuclear-ribonucleoprotein K (hnRNPK) (Bleoo et al., 2001).  
 
p68 (Ford et al., 1988) (Yang et al., 2005) was found consistently overexpressed 
in the colon cancer (Causevic et al., 2001). Recombinant p68 was phosphorylated 
in cancer cell lines but not in normal tissues (Yang et al., 2005). Bale and his 
colleagues (ref) down regulated p68 by RNAi and found that p53 target genes 
were downregulated in response to DNA damage and p53-dependent apoptosis 
specifically. From these observations, they proposed that p68 was recruited 
together with p53 to the p21 promoter and regulated p21 gene expression. This 
implies that p68 may act as a tumor cosuppressor, in concert with p53, on the 
transcription of p53 target genes (Bates et al., 2005). In addition, p68 also 
promotes miR-21 maturation with association of activated R-SMADs and 
DROSHA  (Davis et al., 2008). miR-21 suppresses the programmed cell death 
gene 4 (Pdcd4) that is a tumor suppressor protein (Singh et al., 2009).  
    
DHX9 is capable of linking the C-terminus domain of breast cancer suppressor 
protein (BRCA1) to RNA polII (Aratani et al., 2003). It was also reported that 
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DHX9 bound specifically to the p16/INK4a promoter and upregulated p16 
transcription (Myohanen and Baylin, 2001). DHX9 was also overexpressed 
specifically in lung cancer cells compared to normal counter parts (Wei et al., 
2004). 
   
Besides DHX9, other DHX family members, DHX32, DHX34 and DHX29, were 
also found related to carcinogenesis. DHX32 was found to be overexpressed in 
leukemia cell lines (Abdelhaleem, 2002). DHX34 is a NMD pathways component 
and found to be amplified in human neurohlastomas (Wimmer et al., 1999) (Scott 
et al., 2003). DHX29 is a translation initiation factor and is essential for cancer 
cell proliferation (Parsyan et al., 2009).  
 
Deregulation of RNA transcription, processing, alternative splicing, translation 
and non-coding RNA processing are critical for the development of cancer 
(Abdelhaleem, 2004). Targeting the RNA surveillance accuracy will be a new 
direction for cancer therapy, and RNA helicases could be a new aspect for this 
purpose.  
 
 
1.6 The RHAU gene 
 
RHAU (alias DHX36, G4R1) belongs to DEAH RNA helicase family. It was 
initially identified as a putative RNA helicase in human cells regulating urokinase 
mRNA decay (Tran et al., 2004). Chromosomal location of the human RHAU 
gene is at 3q25.2 while that of mouse RHAU gene at Ch3E1. Since RHAU 
protein is a helicase and binds to the AU-rich element of urokinase mRNA, it was 
termed “RNA helicase-associated with AU-rich elements”. This gene is 
conserved in chimpanzee, dog, cow, mouse, rat, chicken, zebrafish, fruit fly and 
mosquito (NCBI database) but neither in yeast nor nematoda. The lack of RHAU 
homologue in less complex organisms implies that this gene may be evolve for 
the cellular processes that appear in later stages of evolution. According to the 
gene portal system of the Human Gene Atlas database (BioGPS, GNF, Novartis), 
RHAU is relatively highly expressed in hematopoietic cells in both human and 
mouse (Figure 1.6 A and B). This specific expression pattern implies that RHAU 
is important in hematopoietic system.  
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 B 
 Figure 1.6. RHAU mRNA expression in different tissues in (A) human and (B) mouse. Data were obtained from 
(BioGPS, GNF, Novartis). The red lines represent the meadian value of expression.   
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1.6.1 RHAU promotes exosome-associated mRNA decay 
 
Biological function of RHAU was firstly described in 2004 when one of the PhD 
students in Nagamine’s group was studying how the urokinase plasminogen 
activator (uPA) (Alias: PLAU) mRNA stability was regulated. The presence of an 
AU-rich element (ARE) in the 3’UTR of uPA mRNA suggested that the uPA 
protein expression could be regulated at the mRNA stability level. In this study, 
the 3’UTR ARE of uPA mRNA (ARE(uPA)) was immobilized on agarose beads 
and incubated with HeLa cells nuclear extracts. Proteins interacted specifically 
with the (ARE(uPA)) were identified and RHAU was amongst them. Further 
analysis showed that RHAU promoted mRNA decay by recruiting the exoxome 
and poly(A) ribonuclease (PARN) to the message (Tran et al., 2004).  
 
 
1.6.2 RHAU resolves RNA and DNA tetramolecular 
quadruplexes 
 
One year after RHAU was found in RNA decay process, Akman’s group 
identified RHAU/G4R1 as the major source of tetramolecular quadruplex G4-
DNA resolvase activity in HeLa cells (Vaughn et al., 2005). G4-DNA, is also 
called G-quadruplex. G4 was first described in 1988. Single-stranded DNA with 
G rich region will self-associate to form a stable four strand structure at 
physiological concentration (Sen and Gilbert, 1988). This four strand structure 
involves a stack of G quartets arranged vertically. A G quartet involves four 
guanine molecules arranged on the same plane and stabilized by Hoogsteen 
hydrogen bonding and a monovalent cation (Figure 1.7). It was reported that G4-
DNA structures were particularly enriched in certain regulatory elements, such as 
oncogene promoter regions (Siddiqui-Jain et al., 2002; Simonsson et al., 1998; 
Verma et al., 2009), guanine-rich regions of ribosomal DNA, and specific genetic 
control elements, such as immunoglobin heavy chain switch region  (Sen and 
Gilbert, 1988). G4-DNA sequences in these regions are conserved across species, 
implying that G4 has biological importance. After finding that RHAU could 
resolve DNA G-quadruplex, RHAU was found to be able to resolve RNA G-
quadruplex (G4-RNA) as well and even more efficiently than G4-DNA (Creacy 
et al., 2008). Like DNA, guanine rich RNA region can form G-quadruplex 
structure. There are more than fifty thousand G4-RNA sites predicted near mRNA 
splicing and polyadenylation sites in human and mouse genome (Kostadinov et al., 
2006). G4-RNA structures can modulate translation initiation and repress mRNA 
turnover (Kumari et al., 2007).  
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Figure 1.7. Structure of a G-quadruplex. Left: a G-tetrad. Right: an intramolecular G-quadruplex (Neidle and 
Balasubramanian, 2006).  M+ is monovalent cation.  
 
 
1.6.3 RHAU localized to stress granules (SGs) 
 
SGs are special cytoplasmic foci where translationally stalled RNP complexes are 
stored (Kedersha et al., 2005). The RNP complexes consists of polysome-free 48S 
preinitiation complexes, small ribosomal subunits, poly(A)-binding protein 1 
(PABP1) and RNAs. Formation of SGs requires eIF2alpha phosphorylation that is 
induced by various stresses. It was presumed that when cells faces unfriendly 
environmental conditions, cells respond by sending mRNAs to P-bodies for 
degradation or to SGs for storage. These mechanisms allow the cell to quickly 
manipulate the profile of protein expression.  
 
RHAU was found to associate with SGs upon various stresses. Protein deletion 
analysis showed that the first 105 amino acids of the N-terminal domain were 
essential for RNA binding. It was also shown that this RNA-binding domain 
fused with β-gal-EGFP could associate with SGs in response to stress. 
Furthermore, when the ATPase activity of RHAU was abolished by mutating the 
motif II of helicase core domain from DEIH to DAIH, the mutant RHAU was 
found to be recruited to and unable to leave SGs. This indicates that the ATPase 
activity of RHAU modulates the association of RHAU with SGs but the ATPase 
activity was not essential for the recruitment of RHAU to SGs (Chalupnikova et 
al., 2008).   
 
 
1.6.4 RHAU is a nuclear protein 
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Although RHAU was found to be involved in mRNA decay process being 
associated with the exosome and localized in SGs in the cytoplasm, RHAU is 
predominantly localized in the nucleus. As many RNA helicases are multi-
functional, it is not be surprised if RHAU also functions in the nucleus. In HeLa 
cells, GFP-RHAU is localized throughout the nucleoplams and aggregates at 
nuclear speckles. Using transcription initiation inhibitor, Actinomycin D, RHAU 
was found to be localized close to but never overlapping with p68 and p72. In 
vitro coimmunoprecipitation experiments further showed that the interaction 
between RHAU and p68 or p72 was RNA dependent. Previously, it was reported 
that p68-p72 dimer was involved in nuclear processing of miRNA and rRNA 
processing and transcription (Fukuda et al., 2007). The possiblilty cannot be ruled 
out that RHAU is also involved in these processes. By measuring the amounts of 
transcripts at the  steady state level and their half lives using microarray analysis 
method, most genes that showed changes at the steady state level after RHAU 
knockdown were found to be regulated by RHAU at the transcription level rather 
than at the mRNA stability level (Iwamoto et al., 2008). These observations 
suggest RHAU also act as a multifunctional nuclear protein that can modulate 
transcription of subset of transcripts.  
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1.7 Hematopoiesis  
 
In biological view, the hematopoietic system is an important part for maintaining 
healthy physiological condition because it produces all types of blood cells 
required for oxygen transportation, coagulation and fighting against infection. 
This is also a fascinating process because it involves continuous interaction of 
hematopoietic cells with the surrounding environment all over the body and tight 
control of the expression of various genes. Therefore, hematopoiesis is an 
excellent model for studying gene regulation mechanism. 
 
Hematopoiesis is partially conserved in all vertebrates, from fish to amphibian, 
reptile, avian, and mammal (Cumano and Godin, 2007). In the last few decades, 
amphibians, avians and fish were used as model organisms to unravel distinct 
differentiation steps of hematopoiesis. However, due to similarity to humans and 
the availability of gene targeting technique, mouse model has been far more 
attractive and extensively used to dissect the hematopoietic system.  
 
The hematopoietic system involves in at least eight different cell lineages and is 
discussed below.  
 
 
1.7.1 Hematopoietic cells  
1.7.1.1 Erythrocytes: oxygen delivery 
Red blood cells are also called erythrocytes. They contribute to the largest cell 
population in the hematopoietic system. Every day, around 1012 new erythrocytes 
are produced in the body. The major task of erythrocytes is to carry oxygen from 
lungs to all tissues.  
 
1.7.1.2 Blood platelets: hemostasis 
Thrombocytes are called platelets in mice and human. They are derived from 
megakaryocytes. The major function of platelet is to regulate hemostasis by 
forming blood clot to prevent excessive bleeding. In addition, platelets also serve 
as inflammatory mediators (Roitt et al., 2001).  
 
1.7.1.3 Cells for immunity 
In humans and mice, the bone marrow and thymus are the primary lymphoid 
organs where the lymphocytic cells develop. The spleen, lymph nodes and 
lymphoid tissues of the respiratory tracts are the secondary lymphoid organs. 
Hematopoietic cells that are involved in the immune system are called leucocytes 
or white blood cells. There are three types of them: (1) lymphocytes, (2) 
phagocytes and (3) auxiliary cells. Lymphocytes include B cells, T cells and large 
granular lymphocyte. Phagocytes include mononuclear phagocytes, neutrophils 
and eosinophils. Auxiliary cells include basophile, mast cell and platelets. These 
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leukocytes play different roles in the immunity. They work either in innate 
immunity or adaptive immunity. Both immunities are responsible for defense 
against pathogen. Innate immunity respond to a pathogen the same way whether 
or not it was pre-exposed while adaptive immunity is specific for re-exposed 
pathogens with stronger intensity than innate immunity with life-long memory. 
Histocompatibility complex (MHC) plays an important role in the immunity. 
Class I MHC molecules bind to fragmented internal molecules while class II 
MHC molecules are expressed by specialized antigen-presenting cells 
(macrophages, B cells and dentric cells) and bind to fragmented and processed 
foreign particles.  
 
1.7.1.3.1 Lymphocytes 
 
Natural killer (NK) cells are part of large granular lymphocytes and they are 
cytotoxic CD8+ but lack T cell receptors. NK cells are part of innate immunity 
and specialized for attacking tumor cells and viral infected cells that have low 
expression level of major MHC class I on their surface. NK cells can target the 
cells that are bound by antibodies. By binding to the Fc portion of the antibody, 
NK cells are activated to release cytotoxic chemicals stored in the cytoplasmic 
granules. This cytotoxicity leads to apoptosis of the target cells (Hoffbrand et al., 
2006d).  
 
Dendritic cells (DCs) are antigen-presenting cells that interface between the 
innate and adaptive immunity. They process antigens and present it to the helper 
T (TH) cells. They are localized in the skin, lymph nodes and thymus. After 
taking up antigens at infected sites, DCs migrate to the lymph nodes and present 
to B and T cells the foreign molecules together with class II MHC for further 
immune response.  
 
T cells express T cell antigen receptor (TCR). T cell progenitors are produced in 
the bone marrow but their development takes place in the thymus. More than 95% 
of T cells express α and β polypeptide heterodimers and around 5% T cells 
express γ and δ polypeptide heterodimers. These TCRs associate with the CD3 
complex and form the T cell receptor complex (TCR-CD3 complex). The αβ T 
cells are further divided into CD4+ and CD8+ subsets. CD4+ cells help immune 
response and have no cytotoxic or phagocytic ability to kill the infected cells. 
Therefore they are called helper T (TH) cells. They recognize antigens presented 
on the class II MHC molecules on the antigen presenting cells. CD8+ T cells are 
cytotoxic T cells. They can recognize antigens on class I MHC cells. As soon as 
CD8+ cells recognize the infected or dysfunctional somatic cells through the 
antigen on the Class I MHC, they release cytotoxin and kill the cells. The 
different stages of T cell development will be described in the next section.  
  
 
B cells express B cell receptors which are membrane bound immunoglobulins 
(Ig). B cells are responsible for antibodie production and present antigens to T 
cells. There are five classes of antibodies, IgG, IgA, IgM, IgD and IgE. The Ig 
molecules are formed by two heavy and two light chains. Somatic recombination 
 21 
 
of three variable regions, variable (V), diversity (D) and joining (J) segments 
introduce diversity in the heavy chain  (Tonegawa, 1983). The differentiation path 
of B cells will be described in the next section. 
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1.7.1.3.2 Phagocytes 
 
There are two types of phagocytes, mononuclear phagocytes and 
polymorphonuclear granulocytes. These cells are able to engulf pathogens and 
internalize antigens in order to destroy them. Mononuclear phagocytes are a 
group of cells deprived from the same lineage and are long lived. The progenitors 
arose in the bone marrow are called monoblasts. They develop into monocytes in 
blood circulation. The monocytes migrate into the tissues and develop into tissue 
macrophages. Macrophages are particularly enriched in spleen, liver, kidney, 
brain, lung alveolar, bone marrow and lymph nodes. The macrophages in the liver 
are called Kupffer cells in and those in the brain microglias. The macrophages 
either engulf the antigens or present antigens to the T cells. Polymorphonuclear 
granulocytes are not specified for antigen recognition. They are essential for acute 
inflammation. Granulocytes include neutrophils and eosinophils. Neutrophils are 
the most abundant but short lived. Eosinophils are especially capable of targeting 
large parasitic worms by releasing the granulocyte content, there by damaging the 
parasites.   
 
1.7.1.3.3 Audiliary cells 
 
Basophils, mast cells and platelets are auxiliary cells. Basophils are relatively low 
in number in the circulation. Usually they are less than 0.2% of leucocytes. 
Basophils are polymorphonuclear granulocytes but they are not true phagocytes. 
Basophils and mast cells contain granules where heparin, leukotrienes, histamine 
are stored. Basophils and mast cells acts against parasites but also play a critical 
role in autoimmune disorder (Benoist and Mathis, 2002) (Arinobu et al., 2009). 
Platelets are anuclear cells derived from megakaryocytes. Megakaryocytes 
migrate from bone marrow to the lung capillaries and are fragmented into blood 
platelets (Levine et al., 1990). They are not only involved in blood clotting but 
also play a role in inflammation.  
 
Different cell types can be identified by their distinct pattern of markers expressed 
on the cell surface.   
 
    
1.7.2 Origin of hematopoiesis in mouse 
 
The first hematopoietic stem cells detectable in mouse embryo are in 
extraembryonic yolk sac at 7.25 days postcoitus (dpc). Yolk sac is derived from 
mesodermal layer of gastrulation. Certain mesoderm cells differentiate into 
hemangioblasts which are common progenitors of endothelial cells and 
hematopoietic cells (Ueno and Weissman, 2006). Then the cells are arranged in a 
structure in which endothelial cells surround the blood cells. The blood cells 
inside the structure are called blood islands. The first wave of hematopoiesis 
produces primitive erythrocytes followed by primitive megakaryocytes and 
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macrophages  (Cumano and Godin, 2007). At 8 dpc, the yolk sac blood islands 
are connected with intraembryonic blood vessels (McGrath et al., 2003). Then at 
8.5 dpc, intraembryonic hematopoietic precursors appear at aorta-gonad-
mesonephros (AGM) (Cumano and Godin, 2007; Mikkola and Orkin, 2006). 
These cells have multipotent differentiation potential. It was demonstrated that 
the hematopoietic cells in AGM could come from the yolk sac (Samokhvalov et 
al., 2007). At 10 dpc, HSCs seedling to fetal liver occurs after the establishment 
of the circulatory network. Fetal liver is the primary site for hematopoiesis and 
expands during 13 to 16 dpc. Seedlings of HSCs then migrate to the thymus, and 
then the spleen. On 17 dpc, HSCs are seeded in the bone marrow (BM), and 
thereafter the BM remains the primary site of hematopoiesis including the time 
after birth (Cumano and Godin, 2007). However, in case of certain diseases, such 
as osteopetrosis, anemia, thrombocytopenia and splenomegaly, hematopoiesis 
takes place in sites other than bone marrow, for example in spleen. This situation 
is called extra medullary hematopoiesis (Adams and Smuts, 1989).  
 
 
1.7.3 Differentiation road of hematopoietic cells in adult mice 
 
The cells in the hematopoietic system are continuously lost by mechanical 
damage and aging. The cells that have the ability to replenish all the blood cells 
are called hematopoietic stem cells (HSCs). These special cells are capable of 
self-renewal and give rise to all kinds of cells in the blood system when induced 
by  appropriate cytokines and environment (Curry and Trentin, 1967) (Trentin et 
al., 1989). The scheme below shows that all the cell types are originated from the 
HSCs which first differentiate into lineage-restricted progenitors and eventually 
fully differentiated cells of various types (Figure 1.8).   
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Figure 1.8. Hematopoietic cells differentiation pathways. Abbreviations: HSC, haematopoietic stem cell; LT-
HSC, long-term repopulating HSC;ST-HSC, short-term repopulating HSC; MPP, multipotent progenitor; 
LMPP, lymphoid primed MPP; MEP, megakaryocyte/erythroid progenitor; CMP, common myeloid 
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progenitor; GMP, granulocyte/macrophage progenitor; CLP, common lymphoid progenitor; DC, dendritic 
cell; NK, natural killer. The yellow boxes represent the transcription factors and chemokines or cytokines 
required for the differentiation to occur. The dotted lines represent the pathways which are not yet 
determined (Figure adapted from (Graf and Trumpp, 2007) ).  
 
 
There are two types of HSCs, long-term repopulating HSC (LT-HSC) and short-
term repopulating HSC (ST-HSC). Only LT-HSCs are capable of colonizing 
lethally irradiated bone marrow in human or mice and reconstitute the entire 
hematopoietic system for years. ST-HSCs are cells still capable to differentiate to 
different cell types as LT-HSCs but the repopulation period is limited to a few 
weeks only (Morrison et al., 1995). HSCs differentiate into MPPs which have the 
potential to differentiate into the myeloid lineage and the lymphoid lineage. When 
MPPs are committed to the megakaryocyte and erythroid lineage, it becomes 
megakaryocyte/erythroid progenitors (MEPs). In MEPs the differentiation 
potential of the lymphoid lineage is lost. When MPPs become committed to the 
lymphoid lineage, these cells become lymphoid-primed multipotent progenitors 
(LMPPs). In this case, in LMPPs the differentiation potential of the erythroid 
lineage and the megakaryocyte lineage is lost. LMPPs differentiate into common 
lymphoid progenitors (CLPs), common myeloid progenitors (CMPs) or 
granulocyte/macrophage progenitors (GMPs) (not drawn in the picture). CMPs 
can differentiate into GMPs, and GMPs are capable to differentiate into 
neutrophils, monocytes, eosinophils and basophils and mast cells. Esinophils and 
basophils are mainly differentiated directly from CMPs. And evidence shows that 
GMPs can also produce esinophils and basophils in a limited number (Laiosa et 
al., 2006) (Iwasaki et al., 2005) (Arinobu et al., 2005). The CLPs derived from 
LMPPs are capable of differentiating into B cells, T cells and natural killer cells 
(Kondo et al., 1997). In fact, CLPs and CMPs retain plasticity in that CLPs can 
differentiate to macrophages and CMPs to B cells (Laiosa et al., 2006).    
 
 
1.7.3.1 Differentiation of enucleated erythrocytes 
 
Differentiation of enucleated erythrocytes in mammals is called erythropoiesis. 
Transcription factors Gata-1, Gata-2 and FOG-1 are critical for the whole 
erythropoiesis (Ferreira et al., 2005; Kaneko et al., 2010). The first erythrocyte 
lineage committed progenitor cells, proerythroblast, are derived from MEPs 
(Figure 1.9). The development of erythrocytes in bone marrow can be divided 
into four stages. The proerythroblasts undergo cell division and form smaller 
basophilic erythroblasts, which differentiate to smaller polychromatophilic 
erythroblasts, which further develop to still smaller orthrochromic erythroblasts. 
Different stages of erythroblast differentially express CD71 and Ter119 on the 
cell surface. These two markers together with the cell size therefore can be used 
to determine the stage of differentiation of these cells by FACS analysis (Figure 
1.9). The cells are progressively making more hemoglobin at basophilic 
erythroblast stage. After this stage, the nuclei become progressively condensed 
and the amounts of cytoplasmic protein and RNA are decreased. The nuclei are 
finally extruded from orthrochromic erythroblasts which still have some 
ribosomal RNA used for hemoglobin synthesis (Hoffbrand et al., 2006a).  
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Erythropoiesisis regulated by erythropoietin which is a hormone produced by 
interstitial cells in kidney. Erythropoietin is a glycosylated protein of 34 kDa with 
165 amino acids. Its secretion is regulated by oxygen concentration in the blood. 
When an animal is suffering from anemia or other cardiac dysfunction, less 
oxygen is delivered to the kidney. Hypoxia in the blood leads to decrease of 
degradation of transcription factor hypoxia-inducible factor-1 (HIF-1) in cells, 
resulting in the binding of HIF-1 to hypoxia response element at the promoter of 
erythropoietin gene (Shams et al., 2005) (Lok and Ponka, 1999). As a result, 
erythropoietin secretion is enhanced. Erythropoietin activates the GATA-1 gene 
through erythropoietin receptor (EpoR). Activation of GATA-1 expression 
increases bcl-xL protein expression that is essential for maintaining the viability 
of MEP and proerythroblast (Gregory et al., 1999).  
 
The half-lives of normal erythrocyte are around 120 days in humans and 40 days 
in mice (Abbrecht and Littell, 1972; Shemin and Rittenberg, 1946). Erythrocytes 
are constantly exposed to various stresses throughout the circulation. When 
erythrocytes pass through the lung, they are under oxidative stress. When they 
pass through the kidney, they undergo osmotic shock. When they pass through in 
peripheral tissues the capillaries the diameter of which is smaller than theirs, they 
are under mechanical stress. Erythrocyte cell membrane flexibility is 
progressively decreased with age. If the erythrocytes are rigid more than normal, 
these erythrocytes may have tendency torupture when passing through narrow 
capillaries, ensuing haemolysis. The lysed cells will release hemoglobin in the 
extracellular fluid, which will eventually cause renal failure. Therefore, aged 
erythrocytes must be removed from circulation systematically. The aged 
erythrocytes have higher degree of asymmetric distribution of phosphatidylserine 
(PS) on the cell membrane like what is happening during apoptosis in nucleated 
cell. The externalization of PS signals the macrophage in the reticuloendothelial 
system in the spleen and liver to engulf the aged erythrocytes. This process is 
called eryptosis. The iron released from haem (composed of iron and 
protoporphyrin) of erythrocytes is carried to the bone marrow for recycling, while 
the protoporphyrin is broken down to bilirubin. Bilirubin is transported to the 
liver and then combines with glucuronides there and excreted into the gut via bile. 
In the gut, the bilirubin glucuronide is converted to stercobilinogen and 
stercobilin. Part of stercobilin is excreted in faeces and stercobilinogen and 
remaining stercobilin are converted to urobilinogen and urobilin and excreted in 
urine. When the rate of eryptosis or hemolysis is increased, the body compensates 
the loss by increasing the erythropoiesis. However, if erythropoiesis cannot 
compensate the loss of erythrocytes, anaemias ensues (Alvarez et al., 2007; Bosch 
et al., 1994; Bosman et al., 2008; Chen et al., 1999; Cherukuri et al., 2004; 
Hebbel, 1991; Lorenz et al., 1999; Rivera et al., 2006). The basic features of 
haemolytic anemias are jaundice of the mucous membranes and splenomegaly. 
Jaundice is due to unconjugated bilirubin in the blood (Hoffbrand et al., 2006b).  
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Figure 1.9. (Top) Description of erythroblast development in the erythropoiesis organs. (Bottom) Differential 
expressions of cell markers, Ter-119 and CD71, on erythroblasts of different erythroblasts stages. ProE 
represents proerythrocytes, Ery.A represents Basophilic erythroblasts, Ery.B represents polychromalophilic 
erythroblasts and Ery.C represents orthrochromic erythroblasts. CD71 expression increased from ProE and 
reaches the maximum value at Ery.A stage. The CD71 expression then decreased from Ery.A stage until the 
end of erythropoiesis. On another hand, the Ter-119 expression is increased to the highest level once the 
ProE progenitors are committed to the erythrocytes lineage stage. The Ter-119 expression remains high until 
the end of mature red blood cells. The size of cells is decreased progressively throughout the erythropoiesis.  
 
 
1.7.3.2 Differentiation of lymphocytes 
 
The differentiation of lymphoid cells startd when the LMPPs differentiate into 
early lymphoid progenitors (ELPs) that is accompanied by the increased 
expression of recombination-activating gene 1 (Rag1) and Rag2. Rag 1 and Rag 2 
are enzymes that are essential for somatic recombination during formation of B 
cell and T cell receptors (Spanopoulou et al., 1996). ELPs can either migrate to 
thymus to differentiate to T cells or remain in the bone marrow for B cell 
development. The ELPs further develop into CLPs which express interlukein 7 
receptor  alpha on the cell surface(Kondo et al., 1997). CLPs still have the 
potential to develop into B cells, T cells, DCs and NK cells (Figure 1.8).  
 
1.7.3.2.1 B cells differentiation 
 
Those CLPs that express B220 are considered to be the earliest B cell progenitors 
and are called ProB cells. It was shown that transcription factors E2A, early B-
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cell factor (EBF), paired box protein 5 (Pax5), lymphoid-enhancer-binding 
factor1 (LEF1) and sex-determining region Y (SRY) box 4 (Sox4) are essential 
for differentiation of CLP to ProB cells (Zhuang et al., 1996) (Cobaleda et al., 
2007; Hagman et al., 1995; Reya et al., 2000). Then ProB cells develop into Pre-
BI cells where somatic recombination start to occurs. The immunoglobin in B 
cells is composed of two light chains and two heavy chains. The viable region in 
the heavy chain is composed of V, D and J segments. These three segments are 
the gene products of random DNA recombination taking place at V, D and J 
segment genes in the immunoglobin heavy chain locus. PreBI cells undergo 
recombination between D and J segment. Then PreBI develops to be Large PreBII 
cell and V segment joins to DJ segment through DNA recombination. VDJ gene 
is rearranged. This rearranged immunoglobin heavy chain assembles with the 
surrogate light chain to form per-B-cell receptor and is presented on the cell 
surface. Large PreBII cells expand in population. Then RAG1 and RAG2 
expression is enhanced again, and light chain rearrangement occurs joining the V 
and J segments of light chain at the light chain locus. Immature B cells that are 
not autoreactive leave the bone marrow,  move to the spleen and become 
transitional B cells (Hoek et al., 2006). Transitional B cells finally develop into 
mature B cells. Mature B cells are mainly either follicular B cells or marginal-
zone B cells. Follicular B cells form germinal centres together with T cells in the 
spleen after immunization. The B cells in germinal centers undergo proliferation 
and somatic hypermutation at the variable gene segment and undergo isotype 
switching [Reviewed in (Matthias and Rolink, 2005)]. The markers that help to 
identify different stages of B cells are summarized in the figure 1.10.  
 
 
Stages CLP Pro-B cells Pre-BI cells Large Pre-BII cells Small Pre-BII cells
Immature B 
cells Mature B cells
Heavy chain germline undergoes D-J rearrangement
undergoes V-DJ 
rearrangement VDJ rearranged VDJ rearranged
VDJ 
rearranged
VDJ 
rearranged
Light chain germline germline germline
undergoes V-J 
rearrangement VJ rearranged VJ rearranged
lineage  -  +  +  +  +  +  +
IgM  -  -  -  -  -  +  +
IgD  -  -  -  -  -  +
B220  -  +  +  +  +  +  +
CD19  -  -  +  +  +  +  +
CD43  -  +  +  +/-  -  -  -
CD25  -  -  -  +  +  +/-  -
Kit  +  +  +  -  -  -  -  
 
Figure 1.10. Summary of markers for identifying different stage of B cells.  
 
 
1.7.3.2.2 T cell differentiation  
 
T cells develop in the thymus in mice and humans. Different stages of developing 
T cells can be identified by specific markers (Figure 1.11). The thymus does not 
produce T cells progenitors and relies on continuous seedling of progenitors 
produced in bone marrow and transported via blood circulation (Wallis et al., 
1975). The cells that are seeded in the thymus from bone marrow are the early 
lymphoid progenitors (ELPs) (Lind et al., 2001; Medina et al., 2001). It has been 
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shown that CLPs are also capable of reconstituting T cell development in the 
thymus but that circulating CLPs are rare and thus unlikely the major source of T 
cell progenitors in vivo (Schwarz and Bhandoola, 2004). The cells migrate to 
specific sites in the thymus at specific stages throughout the T-cell development. 
ELPs enter the thymus via blood vessels at cortico-medullary junctions. The 
commitment of the T cell lineage from ELPs or CLPs to early T cell precursors 
(ETPs) requires the molecular interaction of Notch-1 ligand with stromal cells in 
the thymus. ETPs proliferate and migrate to the thymus cortex where they 
develop into double-negative 2 stage (DN2). The cells further migrate to sub-
capsular zones where theyare shifted to the DN3 stage and undergo T cell 
receptor (TCR) gene rearrangement of V, D and J segments at the β, γ,δ loci. 
TCR-β combines with pre-Tα to form pre-TCR and is presented on the cell 
surface for β-selection (Fischer and Malissen, 1998). T cells with gene 
arrangement at β chain become αβT cells while those with gene arrangement at 
γ,δ loci become γ,δ T cells. Only those DN3 cells which contain in-frame TCR 
genes are selected for further development (Burtrum et al., 1996). Before fully 
developed into double positive (DP) cells, DN3 cells that pass the β-selection 
migrate to the thymus cortex again and develop into DN4. DN4 then develop into 
immature single positive cells (ISPs), which then develop into the DP stage. 
During this transition, the α chain of TCRt occurs by joining V and J segments. 
At DN4 to ISP transition stage, around 10% of cells undergo TCR α chain 
rearrangement. At ISP to DP transition stage, more than 90% of cell undergo 
TCR α chain rearrangement (Mertsching et al., 1997). After the α chain is 
rearranged, αβTCR is presented on the cell surface and the cells become double 
positive for CD4 and CD8. A knockout mice model revealed that the nuclear 
factor of activated T cells (NFAT) and Sox4 are essential for T cell development 
from DN to DP stage (Schilham et al., 1997). DP cells in the thymus cortex 
undergo positive selection in which only those cells that bind to MHC molecules 
survive. (Those cells that bind to class I MHC molecules become CD8+ T cells 
and those that can bind to class I MHC molecules become CD4+ T cells 
eventually.) Then survival cells migrate towards the medulla of thymus and 
undergo negative selection. During negative selection, T cells areexposed to 
antigen-presenting cells with self-antigen on MHC molecules and those T cells 
that react to self-antigen are eliminated. Finally, survival cells develop into 
SPCD4+ and SPCD8+ cells (Figure 1.12) [Reviewed in (Ceredig and Rolink, 
2002; Rothenberg et al., 2008)].  
 
Stages DN1 DN2 DN3 DN4 ISP DP CD4 CD8
βγδchains undergo D-J rearrangement
undergo V-DJ 
rearrangement
Pre-TCR 
formation
α chain
undergo V-J 
rearrangement
CD117  +++  +++  + low  -  -  -  -
CD44  +++  +++  + low  -  -  -  -
CD25  -  ++  ++ -  -  -  -  -
CD127  -  + low  -  -  -  -  -
CD3  -  - low low low  +  +  +
CD4  -  -  -  -  -  +  +  -
CD8   -  -  -  -  +  +  -  +
 
Figure 1.11. Summary of markers for identifying different stage of T cells.  
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Figure 1.12. Cross-section of adult thymic lobule. Cell migration paths during T cell development are shown 
with arrows. Broken arrows represent the possible pathway of cell differentiation. The differentiation path is 
described in the text. Abbreviation: the early T-cell precursors (ETP); double negative (DN); immature single 
positive (ISP); double positive (DP); single positive (SP) stages (figure is adapted from (Rothenberg et al., 
2008)).  
 
 
Differentiation of T cells involve a network of interacting signals like 
transcription factors, cytokines and chemokines throughout the differentiation 
path (Laiosa et al., 2006). The components that instruct the differentiation of 
hematopoietic cells are found based on knockout mice models. Figure 1.13 shows 
a list of transcription factors that are or might be involved in lineage 
commitments. From the figure, it is demonstrated that loss of function of a single 
transcription factors may have effects on several lineages or only affect one 
lineage. For example, PU.1 and Ikaros knockout mice show defect in most 
lineages, FOG-1 deficiency mice show a defect in T-cell and erythroid cell 
maturation only (Laiosa et al., 2006).  
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Figure 1.13. List of transcription factors involved in hematopoietic lineage commitment. Blue boxes indicate 
affected cell types labeled on the top. Knockout mouse models mentioned here are restricted to loss of 
function of gene by using germ line specific Cre (conventional) and hematopoietic Mx1-Cre or lineage-
specific-Cre. Empty boxes representing no phenotype was reported or observed. Labels denotes as follow: 
lack, indicates the loss of the lineage; matur,  maturational block; func, defect of cellular function; decr, 
decrease in cell numbers; inc, increase in cell numbers. Abbreviations: bZip, basic leucine zipper; HLH, 
helix-loop-helix domain; transmem, transmembrane; HMG box, high motility group box; HTH, helix-turn-
helix domain; RHD, Rel homology domain; ZnF, zinc finger domain. References of each knockout mice 
model refer to the review (Laiosa et al., 2006).  
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2 Materials and Methods 
 
2.1 Generation of RHAU-targeted mice 
 
We targeted the exon 8 of RHAU gene in which the motif II of DExH helicase 
essential for the APTase activity of RHAU resides. The homologous arms 4.5 kb 
upstream and 5.5 kb downstream of exon 8 and exon 8 were amplified by PCR 
from 129/Sv mouse genomic DNA using linker-primers AscI-5'arm-fw (5’-ACC 
AGG CGC GCC GTT CAA ACT ATC TCG TGT TCT ATG CTG C-3’), AscI-
5'arm-rev (5’-ACC AGG CGC GCC GGA TGA GGA GGA AGA GTG TCA 
TGT AG-3’), FseI-3'arm-fw (5’-TGT AGG CCG GCC AGA TAC AGA TCA 
GAT AGT GGG C-3’), FseI-3'arm-rev (5’-ACA AGG CCG GCC AGA AGA 
CTG AAC TAG ATG CCC T-3’), PacI-exon8-fw (5’-CCA GTT AAT TAA 
AAA TGT ACC ACC ACT GTC C-3’) and PacI-exon8-rev (5’-CGT ATT AAT 
TAA GCA AAC TGT CAG CTT AGC C-3’). These fragments were sub-cloned 
into the pGEMT vector (Promega). As a backbone for the replacement targeting 
vector we used pOZIII (Ozgene) with the neomycin resistance gene (NeoR) 
flanked by flippase recognition target (FRT) sites and loxP sites and unique 
restriction sites to introduce the targeted exon and the homologous arms. The 
homologous arms, exon 8 and the HSV-TK gene (for negative selection with 
Ganciclovir, which was not used in this work), each flanked by unique restriction 
sites, were inserted sequentially into the pOZIII vector. The final vector RHAU-
KO was linearized with PvuI and NotI and electroporated into 129Ola ES cells. 
The G418-resistant clones were screened by PCR and Southern blot for 
homologous recombination and the correctly targeted ES cells were used to 
generate chimeric mice with the genotype RHAUfl,neo/+. These were crossed to 
C57BL/6 mice to obtain germ line transmission of the targeted allele. The 
progeny were crossed to B6.129S4-Meox2CreSor (Meox2Cre) to achieve 
deletion of exon 8 and the neomycin cassette from the targeted allele, resulting in 
RHAUΔ/+;cretg mice. RHAUΔ/+;Meox2Creg mice were crossed with RHAU+/+ 
mice to generate RHAUΔ/+ mice free of the Cre transgene.  
 
To remove only the neomycin cassette from targeted alleles, floxed mice with the 
neomycin cassette (RHAUfl,neo/+) were crossed with 129S4/SvJaeSor-
Gt(ROSA)26Sortm1(FLP1)Dym/J mice (Jackson Laboratory) that bore the FLP1 
transgene and expressed FLP1 recombinase (FLPtg). F1 offspring with the 
genotype RHAUfl/+; FLPtg were then selfed to derive RHAUfl/fl mice lacking the 
neomycin cassette and the FLP1 transgene. These new RHAUfl/fl mice were then 
crossed with vav-iCre mice (de Boer et al., 2003) that expressed Cre specifically 
in the hematopoietic system (Almarza et al., 2004) (Zhao et al., 2007). Expression 
of cre can be detectable from stem cells. Offsprings with the genotype RHAUfl/+; 
iCretg were then crossed with RHAUfl/fl or RHAUfl/+ mice to derive RHAUfl/fl; 
iCretg mice for further experiments. RHAUfl/fl littermates were used as a control in 
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most experiments and RHAUfl/+ littermates were used as a control in bone 
marrow transplantation experiments.   
 
We have also established an interferon-inducible RHAU knockout mice specific 
in the hematopoietic system using the MxCre system (Behrens et al., 2002; 
Natarajan et al., 2007). Cre is under the control of Mx1 promoter. When induced 
by interferon, transcription of Cre gene increased in interferon response cells. For 
the production of RHAUfl/fl; MxCretg mice, the breeding plan was similar to that 
for RHAUfl/fl; iCretg mice generation. RHAUfl/fl littermates were used as a control. 
 
Animal experimentation was carried out according to regulations effective in the 
canton of Basel-Stadt, Switzerland. The mice were housed in groups of one to 
eight animals at 25°C with a 12-h light-dark cycle (12 h light, 12 h dark). They 
were fed a standard laboratory diet containing 0.8% phosphorus and 1.1% 
calcium (NAFAG 890; Kliba, Basel, Switzerland). Food and water were provided 
ad libitum. 
 
2.2 Genotyping 
 
A 0.5-mm tail section or a whole embryo was lysed in 300 µL of lysis buffer (100 
mM Tris pH 8, 5 mM EDTA, 200 mM NaCl 0.2% SDS and 50 µg/µL Proteinase 
K). Samples were incubated at 55ºC overnight. DNA was precipitated with 700 
µL absolute ethanol and collected by centrifugation at 20’000 g for 10 min. 
Pellets were washed once with 500 µL 70% ethanol and dried at room 
temperature. DNA was dissolved in 10 mM Tris-HCl pH 8 buffer and incubated 
at 55ºC for 1 h. DNA concentration was measured with 280 nm UV light 
(NanoDrop Technologies, Inc.). For genotyping with PCR, we always use 
PrimeSTARTM HS DNA polymerase (Takara Bio Inc.) and 20 µL reaction 
volume as mentioned in the protocol. For optimal reaction, 100 ng of DNA was 
used. For embryos that were earlier than 7 dpc, all DNA was purified with phenol 
chloroform extraction. Purified DNA sample finally was dissolved in 30 µL of 
10mM Tris-HCl buffer, pH 8.0, and 10 µL of DNA was submitted for every PCR 
reaction. Meox2Cretg allel was identified by PCR using primer one (common: 5’-
GGG ACC ACC TTC TTT TGG CTT C-3’), primer two (Cre: 5’-AAG ATG 
TGG AGA GTT CGG GGT AG-3’) and primer three (wild type: 5’-CCA GAT 
CCT CCT CAG AAA TCA GC-3’) (Tallquist and Soriano, 2000). The wild-type 
and mutant bands were 411 bp and 311 bp, respectively. To identify vav-iCretg 
mice, forward primer (5’- TCA CAC CAG TGA GTG GAA GC-3’) and reverse 
primer (5’-TCC CTC ACA TCC TCA GGT TC-3’) were used. The PCR product 
was ~800 bp. To identify MxCretg mice, forward primer (5’- GCA AGA ACC 
TGA TGG ACA TGT TCA G-3’) and reverse primer (5’- GCA ATT TCG GCT 
ATA CGT AAC AGG G-3’) were used. The PCR product was 462 bp. To 
analyze for exon 8 of the RHAU gene, we used primers KO3-fw (5’-TGT ACA 
TTT TGA TAC TAC TTA ATC TAC CCT TTG A-3’) and KO3-rev (5’- TAT 
GGA AAT GCT CCT AGT TAA AGT TTA GAG CT-3’). The wild-type band 
was 2664 bp, the transgenic band with the targeting vector loxP-Exon8-flp-NEO-
flp-loxP was 4010 bp, the transgenic band with targeting vector loxP-Exon8-loxP 
(without neomycin cassette) was 2229 bp and the mutant band with both exon 8 
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and the neomycin cassette removed by Cre was 1509 bp. To confirm correct 
integration of the targeting vector into the genome, we used two pairs of primer 
sets that flanked the boundaries of the 5’ and 3’ homologous recombination arms 
of the targeting vector. To probe correct integration of the 5’ arm, we used 
primers mod2 (5’- GGG AGA TGG GTG TGT ACT TAT AGA GAA CAG ATG 
TTG-3’) and mod8 (5’-GGC CGA TCC CAT ATT GGC TGC AGG TC-3’). To 
probe the 3’ arm, we used primers mod7 (5’-GAT GCG GTG GGC TCT ATG 
GCT TCT GAG GC-3’); and mod4 (5’- CAA ACT TTC AAT TCC TTT GGC 
TCT TAC AAT CTT AAG TG-3’). Correct integration gave PCR products of 
6365 bp and 6192 bp with primers mod2/8 and mod7/4, respectively. These PCR 
fragments were verified by sequencing.  
 
2.3 Analysis of the efficiency of implantation 
 
Three types of crossing were carried out: male RHAUΔ/+ mice × female RHAUΔ/+, 
male RHAUΔ/+ × female RHAU+/+ and female RHAUΔ/+ × male RHAU+/+. To 
determine the efficiency of implantation of embryos, the numbers of corpora lutea 
(CL) from RHAUΔ/+ (n=25) and RHAU+/+ (n=25) female mice were counted. The 
ratio of the number of implanted embryos to the number of CL denotes the 
efficiency of embryo implantation.  
 
2.4 Western blot analysis 
 
Protein from cells and tissues were extracted with RIPA buffer (10mM Tris pH 
7.0, 150 mM NaCl, 1%w/v Na-deoxycholate, 1% w/v Triton-X 100 and 0.1% 
sodium dodecyl sulfate). Samples were centrifuged at 14000 rpm at 4ºC for 1 
minute. Supernatants were transferred to new 1.5 mL microcentrifuge tubes and 
cell debris pellets were discarded. Protein concentrations in the supernatant were 
determined by micro BCA protein assay (Pierce). Samples were mixed with 6x 
SDS loading buffer (Sambrook, 2001) and submit for SDS-PAGE. Separated 
proteins were transferred to PVDF membrane (Immobilon-P, 0.45 µm, Millipore) 
for western blot analysis. Mouse monoclonal anti-RHAU antibody (YN1) 
generated against a 20-aa peptide, CKKKSDKFLIIPLHSLMPTV, which except 
for the first three amino acids corresponds to amino acids 515-531 of the human 
RHAU and is conserved across species. HRP-conjugated anti-mouse and anti-
rabbit secondary antibodies were used. Signals were developed by ECL detection 
reagent (Amersham Biosciences, RPN2106V1) and detected by Fuji Medical X-
Ray film (FUJIFILM Corporation, Japan).  
 
2.5 Histology 
 
Eight weeks old mice were sacrificed and perfixed with ALPHELYS RCL2®- 
CS100. Organs were embedded after fixation in PBS containing 4% 
paraformaldehyde. Bones were incubated in decalcification solution (20% EDTA 
w/v, 2% NaOH, pH 7.5) for 7 days twice. Decalcificated bones and other organs 
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were subsequently sectioned and stained with hematoxylin and eosin for 
microscopic examination. 
 
2.6 Complete blood count analysis 
 
Blood (ca 200 µL) was collected by tail bleeding into EDTA-coated BD 
Microtainer K2E tubes (BD Pharmingen). Samples were mixed with EDTA by 
shaking the tubes upside down for ten times and kept at room temperature until 
analysis. Complete blood cell counting was performed by the Advia 120 
Hematology Analyzer and results were analyzed by Multispecies Software, 
version 2.3.01-MS (Bayer, Leverkusen, Germany). 
 
2.7 FACS analysis 
 
Eight to ten weeks old mice were used for all FACS analysis. Bone marrow cells 
were recovered by flushing femur and tibia with PBS containing 3% FCS (FACS 
buffer). Splenocytes and thymocytes were collected from whole spleen and 
thymus by pressing gently with a sterile plunger from a 2 mL syringe into the 
FACS buffer. Cells were stained with different antibodies conjugated to a 
chromophore and processed by flow cytometer using appropriate antibodies for 
different cell markers. A list of the reagents, target cells and suppliers is given in 
Suppl. Table 1. A FACSCalibur cytometer (Becton Dickinson) with dual lasers 
(488 and 635 nm) was used for the detection of T cells, B cells, NK cells, 
monocytes and neutrophils, and a MoFlo (DakoCytomation) with three lasers 
(355, 488, and 633 nm) for the detection of LT-HSC, ST-HSCF, MPP, LMPP, 
CMP, GMP, MEP, and CLP cells. Cell sorting was steered with the Summit 
software (DakoCytomation) and the data obtained were analyzed using the 
FlowJo (Tree Star) software. 
 
We determined the absolute number of viable cells in the bone marrow (two 
femurs and two tibias per mouse), spleen and thymus by the trypan blue exclusion 
method and counting in a ViCell counter (Beckman Coulter Inc.). Total cells 
number was multiplied by the percentage of the viable cell gate (DAPI or 7-AAD 
negative) and then by the percentage of cells in each sub-gate thereafter, to 
determine the absolute number of each subpopulation per mouse.  
 
2.8 Bone marrow transplantation  
 
Bone marrow cells were collected from femora and tibiae by flushing with PBS 
containing 3% FCS (FACS buffer) and filtered through 40-µm mesh. 3 x 106 cells 
in 200 µL HBSS were injected into the tail vein of lethally irradiated (1100 cGy 
in 2 doses, separated by 3 hours) seven- to ten-week-old recipient mice. 
C57BL/6SJL-PtprcaPep3b/BoyJ (B6.CD45.1) mice and (GFP)–expressing 
C57BL/6-Tg(UBC-GFP)30Scha/J [Tg(GFP)] mice were used as the recipients. 
Five weeks after bone marrow transplantation, recipient mice which received 
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bone marrow cells from RHAUfl/fl;.MxCretg and RHAUfl/fl control mice were 
treated with poly(inosinic acid)-poly(cytidylic acid) (polyI:C). Chimerism of 
recipient mice was analyzed  for CD45.1 positive and CD45.2 positive cells by 
flow cytometry using anti-CD 45.1-APC (eBioscience) and anti-CD 45.2 PerCP 
Cy5.5 (BD Pharmingen) (Pan et al., 2007).  
 
2.9 Colony forming assay 
 
Bone marrow cells and splenocytes were collected as described for FACS 
analysis. 2x104 bone marrow cells or 1x105 of splenocytes were seeded in 1 mL 
of methylcellulose medium provided from the kit of Mouse Colony-Forming Cell 
Assays Using MethoCult® (M3434, StemCell Technology). Protocol was 
followed as described by the manufacturer. After 12 days, the number of BFU-E, 
CFU-GM, CFU-G, CFU-M and CFU-GEMM in the dish cultured with bone 
marrow cells and spleen cells were counted.  
 
2.10 Determination of the half lives of erythrocytes by in vivo 
biotin labeling 
 
The half lives of erythrocytes were determined by in vivo biotinylation of red 
blood cells. 20 mg/mL of biotin-x-HNS (Sigma) in DMSO was diluted ten folds 
with 0.9% (v/w) NaCl solution. Each mouse was injected with 300 µL (600µg) of 
diluted biotin-x-HNS. Blood samples were collected every day starting one day 
after the injection. Around 2 µL of blood were collected from each mouse into 1 
mL PBS. Cells were counted, and 1 x 106 cells were incubated on ice with 125 µL 
FACS buffer containing 5µg/ mL PE Streptavidin (BD Pharmingen) for 20 
minutes. Cells were washed twice with FACS buffer and submitted for FACS 
analysis. The numbers of biotin positive cells were compared with that obtained 
on the first day. Survival slopes were linear. The Half lives of cells were 
calculated by the formula y = mx + C, where C is the y intercept and is always 
equal to 1, y is the ratio of biotin positive cells, x is the days and m is the slope 
(de Franceschi et al., 2004; Hoffmann-Fezer et al., 1997). 
  
2.11 Determination of the half lives of erythrocytes by in vitro 
biotin labeling 
 
Blood ofRHAUfl/fl mice or RHAUfl/fl; iCre mice was collected in 1.5 centrifuge 
tubes containing  5 µL 5000 IE/UI  heparin in each tube (Pfizer Inc., NY, US). 
Blood cells of the same genotype were pooled and washed twice with twenty 
volumes of PBS. Cells were resuspended in 35 mL PBS (about 20 volumes of the 
blood cell pellet). 5 µL of 20 mg/mL biotin-x-HNS (Sigma) in DMSO was added 
directly in the suspended cells and rotated for 30 min at room temperature. Cells 
were washed three times with 50 mL PBS and resuspended in 1.75 mL PBS to 
give 50% hematoitcrit. Around 200 µL of cell suspension were injected into each 
RHAUfl/fl or RHAUfl/fl; iCretg mouse using a 30G needle. Blood samples were 
 36 
 
collected every day starting one day after the injection. The numbers of biotin 
positive cells were counted in the same way as above mentioned in vivo 
biotinylation experiment, but using 5x106 cells instead.      
2.12 Determination of the osmotic resistance 
 
Blood samples were collected by tail bleeding into EDTA-coated BD Microtainer 
K2E tubes (BD Pharmingen). 2 µL of well mixed blood were added to 200 µL of 
solutions with different NaCl concentrations (0~0.9%) in a 96-well-plate. After 
centrifugation for 5 min at 500g, 80 µL of the supernatant were transferred to 
another 96-well-plate and the absorption at 405 nm was determined, which 
showed the extent of haemolysis. The value of the absorption at different NaCl 
concentrations wase normalized to the absorption at 0% NaCl, which was set as 
100% haemolysis (Foller et al., 2009). The enucleated erythrocytes were sorted 
for osmotic resistance as well. To identify cells with and without nuclei, 2 x 107 
erythrocytes were suspended in 10 mL RPMI containing 10% serum in 15 mL 
tube and  incubated with Hoechst 33324 (10 μg/mL) for 10 minutes at room 
temperature. During cell sorting, erythrocytes with appropriate cell sizes were 
selected by gating with forward and side scatterings. Cells with appropriate cell 
sizes and without Hoechst 33324 signals were collected and submitted for 
osmotic resistance test as above.  
 
2.13 Quantization of plasma concentrations of erythropoietin 
 
Blood samples were collected by tail bleeding into 1.5 centrifuge tubes. Samples 
were allowed to clot for 16 h at 4ºC. Clotted blood was centrifuged at 2000 g for 
20 min. The supernatant was diluted with Calibrator Diluent RD6Z provided 
together with the Mouse/Rat Epo Immunoassay kit (R&D System, Minneapolis, 
USA). The concentration of Epo in the samples was determined according to the 
instructions provided by the manufacture of the kit.  
 
2.14 Annexin V staining of erythrocytes 
 
2µL of blood samples were collected into 1 mL PBS and counted. 1 x 106 cells 
were counted and resuspended in 1 mL Annexin V binding buffer (10mM Hepes, 
pH 7.4, 140mM NaCl, and 2.5 mM CaCl2. 100µL of cells were transferred into a 
new tube and incubated with 5 µL of Annexin V-APC solution (BD Pharmingen) 
for 15 min at room temperature. The cells were mixed with 400µL of Annexin V 
binding buffer and submitted for FACS analysis.  
 
2.15  mRNA microarray analysis 
 
Bone marrow cells were treated as the same way as for FACS data analysis and 
stained with Ter-119 and CD71 for ProE cell sorting mentioned above. Cells were 
sorted in FACS solution and centrifuged for 5 minutes at 4ºC. mRNA were 
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extracted with RNeasy Micro Kit (QIAGEN). RNA was quantified with 
NanoDrop. 200 ng of RNA per sample was submitted for one cycle labeling kit 
from Affymetric according to the manufacturer’s instructions. Samples were 
hybridized on Mouse Gene 1.0 chips. Gene expression values and fold changes 
were analysis by R written by Genome Facility in FMI.  
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3 Results 
 
3.1 Comparison of the primary structure of human and mouse 
RHAU  
 
 
The amino acid sequences of human RHAU and mouse RHAU are aligned. 
According to the alignment results, human RHAU and mouse RHAU are of 91% 
identity and 95% similarity (Figure 3.1).  
 
 
Figure 3.1 Primary structure comparison of human and mouse RHAU showed 91% identity and 95% 
similarity done by MAFFT (Katoh and Toh, 2008) edited in GeneDoc (Nicholas et al., 1997 ). The black 
boxes represent the same amino acids shared by human and mouse RHAU. The grey boxes represent the 
amino acids that are different between human and mouse RHAU but share similar chemical properties.  
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 3.2 RHAU protein is ubiquitously expressed in adult mouse 
 
 
RHAU was detectable by western blot in most tissues collected from adult mice. 
We tested male and female mice in parallel and both showed similar expression 
pattern. Figure 3.2 shows a representative western blot detecting the RHAU 
protein in various organs from a male adult mouse. Due to the low expression 
level of RHAU in the bone marrow cells, we loaded 50µg and 100µg of protein 
from bone marrow cells in the last two lanes in order to detect the expression of 
RHAU. The mouse RHAU is 1008 amino acids in length and the molecular 
weight is 113.8 kDa (predicted by ExPASy Proteomic Server). We could see a 
band corresponding to 113.8 kDa in the gel. The identity of this band was 
confirmed by probing the blot with another anti-RHAU rabbit polyclonal 
antibody (clone 399).  
 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
M is protein marker
1 Brain
2 Heart
3 Lung
4 Pancrease
5 Stomach
6 Intestine
7 colon
8 spleen
9 kidney
10 Thymus
11 Liver
12 muscles from leg
13 spinal cord
14 bone marrow (25 μg)
15 bone marrow (50 μg)
16 bone marrow (100 μg)
rhau100 kDa
75 kDa
 
 
Figure 3.2. Detection of RHAU protein in different tissues of a 16-week old male mouse by western blot. 
Tissues were collected and homogenized in RIPA buffer (10mM Tris pH 7.0, 150 mM NaCl, 1%w/v Na-
deoxycholate, 1% w/v Triton-X 100 and 0.1% sodium dodecyl sulfate) using a microcentrifuge pestle in 2 
mL microcentrifuge tubes. Samples were centrifuged at 14,000 rpm at 4ºC for 1 min. Proteins in supernatants 
were transferred to new 1.5 mL microcentrifuge tubes and cell debris pellets were discarded. 25µg of protein 
from each sample were loaded on each lane for all organs. 50 µg and 100 µg of bone marrow protein were 
loaded in the last two lanes. Arrows on the left shows the protein molecular weight markers of 100 kDa and 
75 kDa (Precision Plus Protein, BioRad). Arrow on the right shows the band corresponding to the RHAU 
protein.  
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3.3 Generation of RHAU-targeted mice 
 
To enable conditional deletion of the RHAU gene, we designed a targeting vector 
in which loxP sites flanked the exon 8 of the RHAU gene and the neomycin-
resistant gene (NeoR) cassette,  which itself was flanked by flp sites, was inserted 
downstream of exon 8,. In the targeted genome, CRE deletes both exon 8 and the 
neomycin cassette while FLP1 deletes only the neomycin cassette (Figure 3.3A). 
The exon 8 encodes the DEIH box of the RHAU that is essential for its ATPase 
activity (Tran et al., 2004) and deletion of this exon introduces a frameshift 
downstream that led to the total decay of the message through the nonsense-
mediated mRNA decay mechanism. The linearized vector was transfected into ES 
cells and cells with a correctly targeted allele (clones 2 and 42) with the genotype 
RHAUfl,neo/+ were detected by Southern blot analysis (Figure 3.3B). PCR analysis 
of these clones using the primer pairs mod4/7 and mod2/8 yielded products of the 
correct sizes (Figure 3.3C). Genotyping of the F1 mice and their offspring using 
the primer pair KO3fw and KO3rev showed three different combinations of two 
alleles (Figure 3.3D). RHAUΔ/+ mice were derived by crossing RHAUfl,neo/+ with 
Meox-CRE mice as described in Materials and Methods. RHAUfl/fl mice were 
obtained by first deleting the neo cassette from RHAUfl,neo/+ and then crossing 
with RHAUfl/+ mice, as described in Methods. 
 
 
 
*   *    *   *    *    *    *    *    *    *    *    *    *    * *   *   *  *   *   *  
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42 2 32 52 63 208139
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Exon8
2 AF AR FF FR8 7
Southern probes
AspI
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AspI AspI
KO3Fw KO3Rev
external probe
PCR products
targeting vector
4
Incorporated 
WT allele
Internal probe
~6.3 kb 
5’ fragment NEO 3’ fragment
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KO3Fw KO3Rev
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1 2 3 1: fl;neo/fl;neo
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Figure 3.3. Generation of RHAU-targeted mice. (A) Schematic representation of the RHAU-targeting vector. 
A targeting vector was constructed by inserting two loxP sites flanking the exon 8 of RHAU and a NeoR. 
Open arrowheads denote the loxP sites and closed arrowheads denote the flp sites. The striped bars indicate 
the positions of the internal and external probes used in Southern hybridizations. Vertical lines indicate AspI 
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restriction sites. (B) Identification of the targeted clones. G418-resistant ES cells were screened for 
homologous recombination by Southern hybridization. DNA samples from ES cells were digested with AspI 
restriction enzyme. One AspI site is introduced into the genome when recombination of targeting vector 
occurs. Internal and external probes were used to identify the clones with correct homologous recombination 
of the targeting vector. The internal probe detected three bands, 15, 10.7 and 6.5 kb, while the external probe 
detected two bands, 15 and 10.7 kb, from the ES cell samples with correct homologous recombination in one 
of the two alleles. Cells without recombination (WT) gave rise to a 15-kb band with both internal and 
external probes. Clones number 42, 2, 52, 63 and 208 contained one allele with the correct integration of the 
targeting vector and a wild-type allele. (C) PCR fragments amplified with primer pairs 2 and 8 and 7 and 4; 
confirmed by sequencing. DNA marker ladders are 10, 8, 6 and 5 kb from the top of the image. (D) 
Genotyping of mice. A primer pair KO3fw and KO3rev was used for genotyping. Crossing mice with 
heterozygous recombination gave rise to mice of three genotypes with the expected Mendelian ratio. 
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3.4 Loss of RHAU caused embryonic lethality but had no effect 
on the implantation efficiency 
 
 
Inbreeding of RHAUΔ/+ mice produced either RHAU+/+ or RHAUΔ/+ but no 
RHAUΔ/Δ offsprings. This indicates that the RHAUΔ/Δ phenotype is embryonic 
lethal. RHAUΔ/+ mice did not show differenct phenotype from wildtype mice.  
 
Following RHAUΔ/+ × RHAUΔ/+ crosses, we found degenerated embryos at 11.5 
days post coitus (dpc). However, genotyping of them was not possible due to poor 
recovery of material. At 8.5 dpc, degenerated fetuses were recovered and 
genotyped as RHAUΔ/Δ (Table 3.1, upper panel). Morphological differences 
between RHAUΔ/Δ and RHAUΔ/+ or RHAU+/+ embryos were observed at 7.5 dpc 
(Figure 3.4). However, at 6.5 dpc, morphologically degenerated embryos were 
not observed although some were RHAUΔ/Δ (Table 3.1 upper section, and data not 
shown). Therefore, RHAUΔ/Δ embryos probably died at around 7.0 dpc. 
 
We also had examined the effect of RHAU ablation on embryo implantation. This 
was achieved by calculating the efficiency of embryonic implantation (the 
number of implanted embryos at 6.5~8.5 dpc divided by the number of corpus 
luteum). The crosses RHAUΔ/+ × RHAUΔ/+ and RHAUΔ/+ × RHAU+/+ gave rise to 
almost identical numbers of embryos born and the same implantation efficiency 
(Table 3.1, Bottom). These results suggest that RHAU ablation does not impair 
embryonic implantation but plays a critical role in embryonic development 
manifested after 6.5 dpc. 
 
Table 3.1. RHAU knockout causes embryonic lethality but does not affect implantation. Top. Embryos 
produced from crossing RHAUΔ/+ and RHAUΔ/+ mice were counted and genotyped. As a control, breeding 
RHAUΔ/+ mice were crossed with RHAU+/+ mice. Embryos with homozygous recombination were not 
detected at 11.5 days after coitus (dpc). Homozygous embryos at 7.5 dpc had already degenerated. 
 
10796----13.5 dpc
--01662211.5 dpc
--4146248.5 dpc
--153212597.5 dpc
--53417566.5 dpc
+/++/+/+ ΔTotal +/Δ
Genotype Genotype
88.98%88.72%rate of implanted embryo
218228implanted embryos
245257total CL counts
2525female mice
Breeding +/Δ x +/\Δ +/+ x +/Δ
Δ/ Δ
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7.5 dpc
RHAU -/-
RHAU 
+/-1mm
Δ Δ
Δ
 
Figure 3.4. RHAU Δ/ Δ embryos was degenerated at 7.5 dpc. Left is RHAU Δ/ Δ embryo and right is control 
RHAU Δ/+ embryo.  
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3.5 Conditional knockout of RHAU in hematopoietic system 
causes anemia 
 
We examined the role of RHAU in hematopoiesis by ablating the RHAU gene 
specifically in hematopoietic cells by means of vav-iCre system as described in 
Materials and Methods. Unlike conventional RHAU knockout mice, RHAUfl/fl; 
iCretg mice were alive at birth and survived for up to at least 6 months old. Mice 
were kept for six months only because of limited space. Pups with a relatively 
pale color at birth (Figure 3.5A) were shown by PCR genotyping to be RHAUfl/fl; 
iCretg. This suggested that these RHAU mutant mice were anemic with a possible 
defect in red blood cell differentiation. Western blot analysis confirmed that the 
RHAU gene was efficiently and specifically deleted in hematopoietic organs as 
RHAU protein was expressed in the spinal cord of RHAUfl/fl; iCretg but not in the 
bone marrow, spleen and thymus (Figure 3.5B). Interestingly, RHAUfl/fl; iCretg 
mice developed splenomegaly and hepatomegaly manifested by increased size 
and higher weight relative to the body mass (Figure 3.5C, D), a phenotype 
frequently associated with anemia (Hoffbrand et al., 2006c). Accordingly, the 
livers and kidneys of RHAUfl/fl; iCretg mice were jaundice. In addition, RHAUfl/fl; 
iCretg mice developed thymic hypoplasia manifested by the smaller size and 
lower weight relative to the body mass (Figure 3.5C, D). However, RHAU 
ablation in hematopoietic cells gave no effect on the total body mass or relative 
weight of kidney (Figure 3.5C, D). RHAUfl/fl; iCretg mice developed smaller bone 
marrow cavities and thicker bones (Figure 3.5E). The distinct structures of red 
and white pulp were absent from the spleens of RHAUfl/fl; iCretg mice (Figure 
3.5E) and, although the thymus of RHAUfl/fl; iCretg mice were smaller than those 
of the wild type, there were no obvious structural changes (Figure 3.5E). 
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Figure 3.5. Phenotypes of RHAUfl/fl; iCretg mice. (A). Anemic appearance of newborn RHAUfl/fl; iCretg mice 
with RHAU ablation specifically in the hematopoietic system. (B) Western blot analysis of the efficiency of 
RHAU ablation in hematopoietic organs. Bone marrow cells were recovered by flushing the femur and tibia. 
Spleen and thymus were pressed gently with a sterile plunger from a 2-mL syringe into PBS. Spleen and 
bone marrow cells were treated with RBC lysis buffer for 7 min on ice. Spinal cord was collected from the 
internal tissue of the backbone. Protein was extracted with RIPA buffer. Aliquots of 50μg of protein from 
bone marrow and 25µg of protein from other tissues were loaded in each lane. 1, 2, and 3 denote the 
genotypes of RHAUfl/fl, RHAUfl/+; iCretg and RHAUfl/fl; iCretg, respectively. (C) Liver, spleen, thymus and 
kidney of RHAUfl/fl; iCretg and control RHAUfl/fl mice. (D) Total body mass and relative body mass of each 
organ from RHAUfl/fl; iCretg and RHAUfl/fl mice. Each dot represents the relative body mass which was 
calculated by dividing the weight of the organ by total body weight. (E) Hematoxylin and eosin staining of 
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paraffin-embedded sections of femur (for bone marrow), spleen and thymus from RHAUfl/fl and RHAUfl/fl; 
iCretg mice. Imagines were taken by Nikon ECLIPSE E600 with 4X magnification using Imagic 
ImageAccess for image calibration with scale bar representing 500μm.  
 
 
3.6 Effects of RHAU knockout on different lineages in 
peripheral blood 
 
To study the effects of RHAU ablation on hematopoietic cells, peripheral blood 
samples from eight-week-old RHAUfl/fl, RHAUfl/+; iCretg and RHAUfl/fl; iCretg 
mice were analyzed (Table 3.2 Group A). Furthermore, in order to confirm that 
the phenotypes observed in RHAUfl/fl; iCretg mice were cell autonomous effects in 
the hematopoietic cells, we performed two bone marrow transplantation 
experiments. Firstly, we used RHAUfl/+; iCretg and RHAUfl/fl; iCretg mice as bone 
marrow cell donors, and used UBC-GFP and BL6.CD45.1 as recipients. 
Complete blood count was performed every two to three weeks after the fifth 
week of transplantation (Table 3.2 Group B1 and B2). Unfortunately, two out of 
three UBC-GFP mice transplanted with bone marrow cells from RHAUfl/fl; iCretg 
mice died at the sixth week post-transplantation. Therefore, counting at the fifth 
week was available only for Group B1. We repeated bone marrow transplantation 
using RHAUfl/fl;Mx-Cretg mice and RHAUfl/fl mice as donors and  UBC-GFP and 
BL6.CD45.1 as recipients. Mx-Cre recombinase activity is interferon inducible 
and can be achieved by injecting polyI:C to the mice. Complete blood count was 
performed every two to three weeks since the fifth week after transplantation 
(Table 3.2A and B, Group C1 and C2).  
 
By comparing the results of complete blood counting between the control mice 
and the target mice (whose hematopoietic cells are RHAU-ablated), we found that 
the mice responded to RHAU ablation consistently in eleven parameters in all 
groups, A, B and C (Table 3.2A and B). Firstly, all RHAU ablated mice were 
anemic with low red blood cell counts (RBC), lowered total hemoglobin (Hb) and 
hematocrit (Hct) counts. These data agree with the phenotypes of the new born 
pups of RHAUfl/fl; iCretg mice which were born anemic. In addition, the mice 
developed reticulocytosis as shown by the enhancement of reticulocytes 
percentages. Secondly, all mice showed reduced platelet counts. Furthermore, all 
RHAU-ablated mice showed decreased counts of white blood cells (WBC). The 
reduction of WBC numbers was mainly due to reduced lymphocytes (lympho) 
because the counts of monocytes (mono), esinophils (esino) and basophils (Baso) 
were not reduced (Table 3.2A and B). Since recipient RHAUfl/fl mice transplanted 
with RHAU-ablated bone marrow cells showed similar phenotypes as RHAUfl/fl; 
iCretg mice, the effects of RHAU ablation in RHAUfl/fl; iCretg mice was cell 
autonomous. Therefore, RHAUfl/fl; iCretg mice were used in the following studies 
on the effect of RHAU ablation on hematopoiesis.  
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Table 3.2. (A) Effects of RHAU ablation in the hematopoietic system on peripheral blood counts. Peripheral 
blood was collected by tail bleeding and characterized as described in Materials and Methods. Parameters 
obtained by this analysis are: white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HB), 
hematocrit (Hct, ratio of blood occupied by RBC), mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width 
(RDW), mean platelet volume (MPV), reticulocyte count (RET),  neutrophils (neutro), lymphocytes 
(lympho), monocytes (mono), eosinophils (eosino) and basophils (baso), large unstained cell (LUC). (A) 
Data of complete blood count. Group A:   complete blood cell counts were analyzed from male RHAUfl/fl, 
RHAUfl/+; iCretg and RHAUfl/fl; iCretg mice at the age of eight weeks old. Group B1 and B2: Complete blood 
cell counts of UBC-GFP and B6.CD45.1 mice after five and twelve weeks of bone transplantation, in which 
the bone marrow was provided from either  control RHAUfl/+; iCretg mice or target RHAUfl/fl; iCretg mice.)   
Group C1 and C2: Complete blood counts of recipient UBC-GFP and BL6Ly5.1 mice after twelve weeks of 
polyI:C treatment. These mice received bone marrow cells isolated from control RHAUfl/fl; MxCretg mice or 
target RHAUfl/fl; MxCretg mice. Mice were treated with polyI:C after five weeks of bone marrow 
transplantation. The detail of bone marrow transplantation and polyI:C treatment was described in the 
Materials and Methods. Efficiency of RHAU knockout induced by polyI:C treatment wasf determined by 
genotyping of individual clone formed in colony forming assay. Results showed 98% and 47% of progenitors 
in bone marrow and spleen, respectively, were RHAU knockout. (B) Summary of blood counts. Red arrows 
show a significant decrease in RHAU-ablated mice compare to the control mice with t- test p value < 0.05. 
Blue arrows show a significant increase in RHAU-ablated mice compare to the control mice with t- test p 
value < 0.05. Dashed arrows show a decrease or increase of values in RHAU-ablated mice compare to the 
control mice with t- test 0.05 < p value < 0.09. Student-t test p value is shown at the bottom of each control 
group. The red values indicate that there are significant differences between the target groups and the control 
groups. SD indicates standard deviation. “n” for each subgroup is presented in first column of the table.  
 
 50 
 
3.7  FACS analysis of different hematopoietic cell lineages in 
spleen, bone marrow and thymus 
 
Unlike in humans, the spleen of adult mice continues to be an accessory 
hematopoietic organ although its role is limited largely to erythropoiesis and 
megakaryocytopoiesis (Slayton et al., 2002). In certain diseases that cause defects 
in hematopoiesis in the bone marrow of mammals including humans, 
extramedullary hematopoiesis in spleens may occur. Therefore, we analyzed cell 
populations in both spleen and bone marrow of control RHAUfl/fl and target 
RHAUfl/fl; iCretg mice.  
 
 
3.7.1 Loss of RHAU leads to erythropoiesis defect 
 
There are four major differentiation stages of erythroblasts that can be identified 
in hematopoietic organs: ProE, Ery.A, Ery. B and Ery.C. An examination of of 
these erythroblasts (Figure 3.6)  in the bone marrow RHAU-ablated mice showed 
dramatic increases in ProE from 1.8 to 10.9% and in Ery.A from 24.3 to 41.7% 
(Figure 3.6B). In contrast, Ery.B and Ery. C decreased from 25.4 to 13.6% and 
from 48.5 to 33.6%, respectively (Figure 3.6A). In the spleen, ProE increased 
markedly from 0.7 to 11.8% and Ery.A from 6.7 to 22.9%. The proportion of Ery. 
B did not change and Ery. C decreased from 84.7 to 54.9% (Figure 3.5A). In 
terms of total numbers of erythroblasts, a marked difference in the response to 
RHAU ablation was found between the two organs (Figure 3.6C). Since it would 
also be interesting to see whether RHAU ablation affects the total number of 
erythroblasts, we calculated the total cell number of each population. By 
multiplying the cell numbers by the percentages of particular cell types 
determined by FACS, we obtained the absolute numbers per organ. In bone 
marrow, total erythroblasts decreased by 37%, in which Pro.E increased and 
Ery.B and Ery.C decreased significantly. In contrast, total erythroblasts in the 
spleen increased dramatically 4.7-fold, with all subgroups contributing to the 
increase.  
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Figure 3.6. Differential effects of RHAU ablation on erythroid cell differentiation in the bone marrow and 
spleen. (A) Effect of RHAU ablation on the distribution of four stages of erythroblasts. The different stages 
were identified in FACS by probing Ter-119 and CD71 together with a forward scatter (FSC) parameter (Liu 
et al., 2006). All Ter119-positive cells are classified into four subgroups: ProE (Ter119med CD71hi), Ery.A 
(Ter119hiCD71hiFSChi), Ery.B (Ter119hiCD71hiFSClow) and Ery.C (Ter119hiCD71lowFSClow). The 
mean proportions of each subgroup with standard errors (n=4) are shown at the top of the boxes in dot plot 
graphs. (B) Effect of RHAU ablation on total numbers of erythroid cells in bone marrow and spleen. Cell 
numbers of the four subgroups were also calculated based on their percentages and are indicated in the bars 
by different shades that denote, from the top, Pro.E, Ery.A, Ery.B and Ery.C. *p<0.05, n=4.  
 3.7.2 Loss of RHAU leads to changes in granulocyte and 
lymphoid cell numbers 
 
Monocytes and neutrophils can be distinguished with two markers, Mac-1 and 
Gr-1 (Lagasse and Weissman, 1996). As shown in Figure 3.7, monocytes were 
more abundant in both bone marrow and spleen of RHAU-ablated mice than in 
wild-type mice, while neutrophils were less abundant. When total cell number in 
each organ was considered, monocytes appeared to have declined in the bone 
marrow but increased in the spleen (Figure 4A, lower panel). Total cell number 
neutrophils were decreased in both organs (Figure 3.7A).  
 
Lymphoid cells include natural killer (NK) cells, B cells and T cells. The 
percentage of DX5+ NK cells was not affected by RHAU ablation either in the 
bone marrow or the spleen (Figure 3.7B). However, the total number of NK cells 
was strongly reduced in bone marrow and slightly increased in spleen of RHAU-
ablated mice (Figure 3.7B, bottom panel). 
 
B cell maturation proceeds in the bone marrow from the very early Pro-B cell to 
immature B cells. Immature B cells enter the peripheral circulation, seed in the 
spleen and undergo further differentiation (Matthias and Rolink, 2005). CD19 is a 
marker that is expressed on all B stages cells from early Pro-B cells. Loss of 
RHAU strongly reduced the fraction of CD19+ cells in both bone marrow and 
spleen (Figure 3.7C, dot plots). Despite the splenomegaly in RHAU-ablated mice, 
the total number of B-cells in the spleen of these mice was still much lower than 
in control spleens, suggesting that not all cell types were increased to the same 
degree of splenomegaly (Figure 3.7C, lower panels). 
 
Progenitors of T cells leave the bone marrow and migrate to thymus for T cell 
differentiation. T cell maturation in the thymus proceeds from double negative 
cells (DN, CD3-CD4-CD8-) to immature single positive cells (ISP, CD3-CD4-
CD8+), then to double positive cells (DP, CD3+CD4+CD8+), and finally to either 
single CD4+ (CD3+ CD4+CD8-) or single CD8+ cells (CD3+CD4-
CD8+)(Ceredig and Rolink, 2002; MacDonald et al., 1988). Different 
differentiation stages of T cells in the mice were analyzed with CD3, CD4 and 
CD8 markers. The percentages of ISP8 and DN cells were elevated in the thymus 
of RHAU-ablated mice (Figure 3.7D, dot plots). However, the percentage of 
mature SP cells did not change (Figure 3.7D, histograms). When we compare the 
absolute number of thymocytes in RHAU-ablated mice to control mice, we found 
that there were less DN cells, no change in ISP8 cells and finally less SPCD4+ 
and SPCD8+ cells. Furthermore, we also found that the majority of ISP8 cells 
from RHAU-ablated mice were CD3low. Thus, progression from the ISP8 stage 
to the mature SP stage appears to be retarded when RHAU was removed.  
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Figure 3.7. Organ-specific effects of RHAU ablation on different hematopoietic cell lineages. (A) Effect of 
RHAU ablation on monocytes and neutrophils. Monocytes and neutrophils were identified as Gr-1-/lowMac-
1high (left area) and Gr-1highMac-1high (right area), respectively. The mean percentages with standard 
errors (n=4) are shown at the top of the boxes in dot plot graphs. The bar charts below show the absolute 
numbers of monocytes and neurtophils recovered from the mice. *P<0.05, n=4. (B) Effect of RHAU ablation 
on NK cells. NK cells were identified as low side-scattering and DX5+ cells. The mean percentages with 
standard errors (n=5 for bone marrow; n=4 for spleen) are shown at the top of the boxes in dot plot graphs. 
The bar charts show the absolute number of NK cells. *P<0.05, n=4. (C) Effect of RHAU ablation on B cells. 
B cells were identified by low SSC-H and CD19+ cells. The mean percentages with standard errors (n=4) are 
shown at the top of the boxes in dot plot graphs. The bar charts below show the absolute number of B cells. 
*P<0.05; n=4. (D) Effect of RHAU ablation on T cells. T-cell progenitors at different stages of 
differentiation were first monitored by CD4 and CD8 expressions. The means proportions percentages with 
standard errors (n=4) are shown in corresponding sections of dot plot graphs. Single CD8+ cells were further 
characterized for CD3 expression to distinguish between immature (ISP8) and mature single CD8+ cells 
(histogram). The bar charts show absolute numbers of different T-cell progenitors. *P<0.05, n=4. 
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3.7.3 Characterization of hematopoietic progenitors in RHAU-
ablation mice showed a shift of progenitor and stem cell 
populations 
 
 
Previous FACS analysis showed that loss of RHAU led to differentiation defects 
in both myeloid and lymphoid lineages. We speculated that RHAU ablation 
affected differentiation at its early stage before cells committed to any specific 
lineage. By FACS analysis, we examined whether RHAU ablation affected 
progenitor cells, including megakaryocyte/erythroid progenitor (MEP), 
granulocyte/macrophage progenitor (GMP), common myeloid progenitor (CMP), 
common lymphoid progenitor (CLP), lymphoid primed multipotent progenitor 
(LMPP), short-term repopulating HSC (ST-HSC) and long-term repopulating 
HSC (LT-HSC). Of these, we first examined the CMP, GMP, MEP and CLP cell 
populations. CMP, GMP and MEP were examined simultaneously. RHAU 
ablation significantly enhanced the MEP fraction but reduced GMP and CMP 
cells, both in bone marrow and spleen (Figure 3.8A). However, RHAU ablation 
had no effect on total CMP cell number either in bone marrow or spleen, but 
significantly decreased GMP cell number in bone marrow and increased MEP cell 
number in spleen (Figure 3.8C). Interestingly, RHAU ablation led to elevated 
levels of CLPs in percentage as well as in total cell number (Figure 3.8B, C).   
 
The LT-HSC, ST-HSC and LMPP populations were examined simultaneously. 
As shown in Figure 3.8D, the percentage of LT-HSC cells increased in response 
to RHAU ablation whereas that of ST-HSC and LMPP cells decreased. In terms 
of absolute cell number, both LT-HSC and ST-HSC cells increased and LMPP 
did not change (Figure 3.8D). In RHAU-ablated bone marrow, LT-HSC cell 
numbers were elevated 5.8-fold. The elevation of ST-HSC cells, which are 
derived from LT-HSC, was only 2.8-fold and, finally, the elevation of 
downstream MEP and LMPP cells was negligible (Figure 3.8E).  
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Figure 3.8. Effects of RHAU ablation on progenitors and stem cells. (A) FACS analysis of MEP, GMP and 
CMP cells in bone marrow and spleen. The lineage-negative, CD127Ra-negative living cells were gated and 
analyzed for c-kit positive and Sca-1 negative populations (LK). The LK subgroup was further gated for 
CD34 and CD16/32 (FcγR). CMP, GMP and MEP were were identified as FcγRlowCD34+, 
FcγRhighCD34+ and FcγRlowCD34-, respectively. The mean proportions of CMP, GMP and MEP cells 
with standard errors are indicated in the graphs. * P<0.05, n = 6. (B) FACS analysis of CLP cells in bone 
marrow and spleen. Cells were first gated for lineage-negative and CD127Ra positive living cells. This 
population was further probed for f c-kit and Sca-1. CLP cells were defined as C-kit+Sca-1+ double-positive 
populations. The mean proportions of CLP cells with standard errors are indicated in the graphs. *P<0.05, n 
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= 6. (C) Absolute numbers of progenitor cells in bone marrow and spleen. * P<0.05, n=6. (D) FACS analysis 
of LT-HST, ST-HST and LMPP cells in bone marrow. Lineage negative bone marrow cells were first gated 
to obtain IL-7Ra-Sca-1+c-Kit+ cells, which were further gated into two populations Thy1.1low (Thy1.1+) 
and Thy1.1neg (Thy1.1-) (upper panel). These were further probed for VCAM-1 and Flt3 (CD135) 
expression (lower panel). LT-HSC, ST-HSC and LMPP were defined as Thy1.1+ VCAM-1+ Flt3-, Thy1.1+ 
VCAM-1+ Flt3+ and Thy1.1-VCAM-1-Flt3+, respectively. The mean proportions of different populations 
with standard errors are indicated in the graphs. *P<0.05, n=6. (E) Effect of RHAU ablation on the numbers 
of stem cells. The mean numbers of each cell type with standard errors are shown as bar charts. *P<0.05, n=6.  
 
 
3.7.4 Loss of RHAU leads to progressive reduction of population 
expansion ability in hematopoietic stem cells and 
erythroblasts  
 
When we were calculating the absolute numbers of LT-HSCs, ST-HSCs and 
LMPPs, we found that there was a progressive decrease in the ratio of cell 
number in RHAU-ablated mice over that in control mice through differentiation 
(Figure 3.9A). It suggests that RHAU ablation suppresses population expansion 
and reduces differentiation potential of hematopoietic stem cells.  
 
We also observed a similar tendency in the erythrocyte differentiation in bone 
marrow and spleen. MEPs have the potential to differentiate into either 
megakaryocytes or erythrocytes. Once MEPs have differentiated to ProEs they 
are fully committed to the erythrocytic lineage. When RHAU was knockout, 
MEPs in bone marrow did not change in number significantly and increased by 
3.2-fold in spleen. ProE cells increased in number 3.6- and 74-fold in bone 
marrow and spleen, respectively. Elevation of the numbers of the subsequent 
Ery.A cells declined to 1.1- and 14-fold in bone marrow and spleen, respectively. 
Finally, changes in Ery.B and Ery.C cells were 0.4-fold in bone marrow and 5.7- 
and 3.2-fold, respectively, in the spleen (Figure 3.9B). Although the Ery.C 
number increased in the RHAU-ablated spleen and decreased in the RHAU-
ablated bone marrows, the progressive reduction in population expansion ability 
was consistent in the two organs.  
 
To confirm that decrease in population expansion and differentiation potential of 
hematopoietic stem cells were caused by RHAU ablation in these cells, we 
performed competitive bone marrow transplantation experiments. Lethally 
irradiated BL6.CD45.1 mice were used as recipients and transplanted with 
mixtures of bone marrow cells. The cell mixtures were either composed of (i) 
UBC-GFP and RHAUfl/fl in a 1 to 10 ratio, or  (ii) UBC-GFP and RHAUfl/fl; 
MxCretg in a 1 to 10 ratio. The mice were then divided into three groups. In 
Group 1, three recipient mice were transplanted with UBC-GFP and RHAUfl/fl 
cells. In Group 2, four recipient mice were transplanted with UBC-GFP and 
RHAUfl/fl; MxCretg cells. In Group 3, four recipient mice were transplanted with 
UBC-GFP and RHAUfl/fl; MxCretg cells. Mice from group 1 and 2 were treated 
with polyI:C after five weeks of transplantation (described in Materials and 
Methods) and group 3 were not treated. We used anti-CD45.1 and anti-CD45.2 to 
distinguish between leukocyte sources: recipients and donors. The UBC-GFP 
donor cells were positive for GFP expression. CD45.2+GFP- leukocytes were 
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considered to be derived from RHAUfl/fl or RHAUfl/fl; MxCretg donors. Before 
polyI:C treatment,  there were 90.7%, 90.3% and 91.3% CD45.2+ leukocytes in 
Group 1, 2 and 3, respectively. This indicates that the majority of cells were 
derived from donors. Amongst CD45.2+ leukocytes, 88.7%, 80.7% and 84.0% of 
them were GFP- in Group 1, 2 and 3, respectively (Figure 3.9C, Leukocytes, 
time=0). By treating the mice with polyI:C, RHAU was ablated in the 
hematopoietic cells of the genotype RHAUfl/fl; MxCretg (Group 2). The ratio 
CD45.2+GFP- cells over  total CD45.2+ cells [CD45.2+GFP- / (CD45.2+GFP- + 
CD45.2+GFP+)] was monitored after one week of polyI:C treatment. The 
changes of the ratio were recorded every two weeks. As expected, only Group 2 
RHAU-ablated hematopoietic cells showed progressive reduction in population 
(Figure 3.9C). The reduction became significant after three weeks of the 
treatment. The reduction of leukocytes in RHAU-ablated conditions could be 
explained by depletion of B cells because there was a dramatic decrease of B cells 
in the RHAUfl/fl; iCretg mice. On the other hand, the reduction of erythrocytes was 
faster than leukocytes and reached the steady state after seven weeks of the 
treatment. This was due to the shorter half lives of erythrocytes compare to 
leukocytes. These results suggest that GFP+ leukocytes and erythrocytes out-
grow RHAU-ablated cells (Group 2: RHAUfl/fl; MxCretg + polyI:C) but not 
RHAU-expressing cells (RHAUfl/fl + polyI:C or RHAUfl/fl;MxCretg without 
polyI:C). These results support the idea that the decrease in population expansion 
and differentiation potential was caused specifically by RHAU-ablation and was 
cell autonomous.  
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Figure 3.9. Loss of RHAU leads to progressive reduction of population expansion ability in the 
hematopoietic cells. (A) Effect of RHAU ablation on the number of stem cells. The mean numbers of 
different cell types with standard errors are shown as bar charts. The number at the top of two bars in each 
graph indicates the fold change after RHAU ablation. Arrows indicate the path of early hematopoiesis. 
*P<0.05, n=6. The numbers of stem cells presented in this figure are the same as those presented in Figure 
3.9E. (B)The numbers of MEP, ProE, Ery.A, Ery.B and Ery.C cells in bone marrow (left panel) and spleen 
(right panel) are shown. The number at the top of two bars in each graph indicates the fold increase after 
RHAU ablation. The order of cell differentiation in the erythrocytic lineage is MEP Æ ProE Æ Ery.A Æ 
Ery.B Æ Ery.C. *P<0.05; n=6 for MEP and n=4 for other cell types. (C) Progressive reduction of RHAU-
ablated hematopoietic cells in population expansion ability was demonstrated in competitive repopulation 
assay. Two different combinations of bone marrow cells, (i) UBC-GFP and RHAUfl/fl in a 1 to 10 ratio and (ii) 
UBC-GFP and RHAUfl/fl; MxCretg in a 1 to 10 ratio, were transplanted into three and eight BL6.CD45.1 mice, 
respectively. The mice were divided into three groups. Group 1, recipient mice were transplanted with UBC-
GFP and RHAUfl/fl cells (n=3)   Group 2, recipient mice were transplanted with UBC-GFP and RHAUfl/fl; 
MxCretg cells (n=4). Group 3, recipient mice were transplanted with UBC-GFP and RHAUfl/fl; MxCretg cells 
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(n=4). Mice from Groups 1 and 2 were treated with polyI:C after five weeks of bone marrow transplantation 
(described in Materials and Methods) and Group 3 were not treated with polyI:C.  *P<0.05 
 
3.7.5 In vitro colony forming assay  
 
FACS analysis showed changes in cell number distribution among monocytes, 
neutriphils and erythroblasts. In vitro colony forming assay supported our 
observation. Equal number of bone marrow cells and splenocytes isolated from 
either RHAUfl/fl or RHAUfl/fl; iCretg mice were plated in 1 mL MethoCult® 
Methylcellulose-Based Medium in 35 mm dish. Colonies were counted after 
twelve days. The number of colonies formed can reflect the differentiation 
potential of the precursor cells. When RHAU was ablated, the BFU-E count 
deceased in bone marrow culture but increased in splenocyte culture. This result 
corroborates the result of FACS analysis that the erythroblast numbers were 
decreased in the bone marrow but increased in the spleen. At the same time, CFU-
M, CFU-GM and CFU-GEMM cells were increased in splenocyte cultures 
(Figure 3.10). CFU-GEMM cells are derived from the progenitors that have 
potential to differentiate into erythrocytes, megakaryocyte, monocyte and 
granulocyte. CFU-GM cells are derived from more lineage committed progenitors 
that can differentiate into granulocyte and monocytes. CFU-G and CFU-M 
derived from the progenitors that can differentiate into granulocytes and 
monocytes, respectively. The differentiation pathway can be expressed as CFU-
GEMM Æ CFU-GMÆ CFU-G or CFU-M. Since there was no change of CFU-G 
counts but increase of CFU-M counts, it is concluded that RHAU ablation 
enhanced differentiation potential of monocytes in the spleen. Also, CFU-M 
counts increased in bone marrow cell culture. These results support the FACS 
data that monocytes percentage was increased in the bone marrow and the spleen.  
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Figure 10. Loss of RHAU resulted in higher CFU-M counts both in the bone marrow and spleen, higher 
BFU-E, CFU-GM and CFU-GEMM counts in the spleen and lower BFU-E count in the bone marrow. 
Unfractionated 2x104 cells bone marrow or 105 splenocytes excluding the red cells were plated in 1mL 
methylcellulose-base media supplied. Colonies were counts after 12 days of seedling. This figure is a 
representative result, *p< 0.05, student's t-test, n = 3, experiment was repeated in triplicates and similar 
results were obtained. 
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From complete blood counting and FACS analysis, it was found that the loss of 
RHAU led to decreased differentiation potential of the erythrocyteand lymphoid 
cell lineages but to increased differentiation potential of the monocyte lineage. 
Next, we further characterized the anemic phenotype of RHAUfl/fl; iCretg mice.  
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3.7.6 Quantization of plasma concentrations of erythropoietin 
 
Since RHAU-ablated mice were anemic, we wanted to know whether the animals 
produced appropriate amount of erythropoietin to respond to anemia. As shown in 
Fig. 3.11, RHAUfl/fl; iCretg mice showed 800 times higher erythropoietin 
concentration in blood than RHAUfl/fl control mice (Figure 3.11). This implies 
that RHAUfl/fl; iCretg mice responded to anemia by enhancing erythropoietin 
levels in blood in order to promote erythrocytosis. According to the results of 
complete blood counting, RHAU-ablated mice developed reticulocytosis. This 
indicates that RHAU-ablated mice responded to enhanced Epo.  
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Figure 3.11 Increased erythropoietin level in blood plasma of RHAUfl/fl; iCretg mice. *p<0.05, n=6 for each 
group.  
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3.7.7 Blood smear examination showed spherocytosis in the 
RHAUfl/fl; iCretg mice 
 
Spherocytes could be detected in the blood of RHAUfl/fl; iCretg mice suggesting 
the possibility of hemolytic anemia (Figure 3.12). 
 
 
 
 
 
Figure 3.12 Blood smear examination showed spherocytes were present (pointed with arrows) in RHAUfl/fl; 
iCretg mice. Top. RHAUfl/fl.  Bottom. RHAUfl/fl iCretg 
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3.7.8 Determination of the osmotic resistance 
 
Since the blood smear test showed that the mice might have developed hemolytic 
anemia through genetic defects of some skeleton membrane protein, we tested the 
fragility of the erythrocytes. We placed the blood cells of these mice in aqueous 
solutions of different NaCl concentrations ranging from 0% (pure water) to 1% 
w/v. All erythrocytes are disrupted in pure water and we set this as the reference 
point. The calculation of percentages of disrupted cells was described in the 
Materials and Methods. Surprisingly, between 0.35 and 0.65% w/v of NaCl, more 
RHAUfl/fl erythrocytes were disrupted than RHAUfl/fl; iCretg erythrocytes. The 
osmotic resistance curve of RHAUfl/fl; iCretg erythrocytes shifted to the left of the 
curve of RHAUfl/fl control erythrocytes (Figure 3.11A). This implies that 
erythrocytes of RHAUfl/fl; iCretg mice are more resistant to osmotic shock 
compared to control erythrocytes. Since there were more reticulocytes present in 
the blood of RHAUfl/fl; iCretg than RHAUfl/fl mice, which might have interfered 
with the sensitivity of the cells to low osmolarity, we isolated mature erythrocytes  
excluding cells that carried nucleic acid by cell sorting (Materials and Methods). 
Consistently, the erythrocytes from RHAUfl/fl; iCretg mice showed higher osmotic 
resistance at 0.55% of NaCl (Figure 3.11B) in both sorted and unsorted cells, 
indicating that erythrocytes from RHAUfl/fl; iCretg mice were indeed more 
resistant to low osmolarity.  
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Figure 3.11. Enhanced osmotic resistance in RHAUfl/fl; iCretg erythrocytes. (A) Blood cells from RHAUfl/fl 
and RHAUfl/fl; iCretg mice were plated in different concentration of NaCl from 0% w/v (pure water) to 
maximum 0.9% w/v. This figure represents one representative experimental result, n=3 for each group. 
Experiment was repeated and similar results were obtained. (B) Both unsorted blood cells and sorted 
enucleated erythrocytes from either RHAUfl/fl or RHAUfl/fl; iCretg mice consistently showed significantly 
enhanced osmotic resistance.  
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3.7.9 Chasing of biotinylated erythrocytes revealed shortening of 
half lives of erythrocytes in RHAU knockout condition  
 
From the results of complete blood cell counts, we know that RHAU-ablated 
mice are anemic. At the same time, there was a higher number of reticulocytes in 
the RHAU-ablated mice including those mice that received bone marrow 
transplantation. The reticulocytes are immature erythrocytes released from 
hematopoietic organs. Reticulocytes continue to develop into mature erythrocytes 
and circulate in the peripheral blood until the end of their lives. The higher 
number of immature reticulocytes and the lower number of total erythrocytes 
suggested a higher turn over rate of erythrocytes in RHAUfl/fl; iCretg mice. 
Therefore, we measured the half lives of erythrocytes in control RHAUfl/fl and 
RHAUfl/fl; iCretg mice. Firstly, we labeled the erythrocytes by injecting biotin-x-
HNS directly into the blood circulation. The half life of erythrocytes in each 
mouse was calculated as described in the Materials and Methods. We found that 
the half lives of erythrocyte of RHAUfl/fl and RHAUfl/fl; iCretg were 22 days and 
11 days, respectively (Figure 3.12A). From this result, we conclude that RHAU 
ablation leads to shortening the half life of erythrocytes.  
 
Next, we repeated to measure the half lives of erythrocytes. This time, we first 
labeled the erythrocytes from RHAUfl/fl or RHAUfl/fl; iCretg ex vivo (as described 
in the Materials and Method) and then transfused into RHAUfl/fl or RHAUfl/fl; 
iCretg mice. We found that the half life of erythrocyte from RHAUfl/fl mice was 22 
days from this experiment. This result was similar to that obtained from in vivo 
biotin labeling experiment. Surprisingly, when the erythrocytes from RHAUfl/fl; 
iCretg mice were transfused to RHAUfl/fl mice, the average half life was 20 days 
and showed no significant difference from that of RHAUfl/fl erythrocyte. On the 
other hand, we found that the average half life of erythrocytes from RHAUfl/fl; 
iCretg mice decreased to 15 days when transfused into RHAUfl/fl; iCretg mice 
(Figure 3.12B). The decrease was significant. Therefore, the shortening of the 
half life of erythrocytes in RHAUfl/fl; iCretg mice was due to “extrinsic” effect.  
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Figure 3.12. Half lives of erythrocyte from RHAUfl/lf; iCretg mice specifically reduced in RHAUfl/fl; iCretg 
mice but not in RHAUfl/fl mice. (A) Shortened life-span of erythrocytes in RHAUfl/fl; iCretg mice.The half life 
of erythrocytes was determined by chasing biotinylated cells in vivo. Each dot represents a half life value of 
erythrocytes from each mouse. (B) Shortened life-span of RHAUfl/fl; iCretg erythrocytes in RHAUfl/fl; iCretg 
mice and RHAUfl/fl mice. The horizontal lines show the average values and presented at the bottom of the 
graph. *P<0.05, n=6 for RHAUfl/fl and n=5 for RHAUfl/fl.  
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3.7.10 Comparison of ProE transcriptomes of RHAUfl/fl control 
mice and RHAUfl/fl; iCretg mice revealed an enrichment of 
genes with G-quadruplexe motifs at their promoters  
 
Since we observed a defective expansion of cells in erythrocyte lineages, we 
speculated the effect of RHAU on the gene expression in ProEs. ProE is a stage of 
erythroblast which proliferates extensively during population expansion. In order 
to compare the transcriptome of ProEs from control RHAUfl/fl mice and RHAUfl/fl; 
iCretg mice, 1 x 107 bone marrow cells were labeled with FITC anti-Ter119 and 
PE anti-CD71 antibodies. ProEs (Ter119medCD71hi) were sorted with MoFlo 
(DakoCytomation) operated with the software Summit (DakoCytomation). Two 
control and two target mice were used and ProEs collected from one mouse were 
treated as one sample. RNA samples were submitted for transcriptome analyses 
using Affeymetrix microarray chip as described in Materials and Methods. A list 
of genes that were deregulated in RHAU-ablated ProEs was made by program 
written in R with a two-fold change cutoff and p value < 0.01 (Appendix). The 
gene list was imported to Ingenuity Pathways Analysis (Ingenuity system) and 
genes were grouped according to biological pathways (Table 3.3A). Since we 
were interested in the genes that regulated cell death and proliferation that lead to 
the phenotype of the RHAUfl/fl; iCretg mice, the genes that were involved in cell 
death and cell cycle regulation pathways were listed and grouped according to the 
localization of the gene products. Furthermore, we also searched for genes which 
contain potential G-quadruplex motifs in the promoter regions, genes contain G-
quadruplex motifs in the RNAs and genes that contains AU-rich element in the 
3’UTR of mRNA. The databases used for motif search were listed in the 
Materials and Methods.  
 
According to the Greglist databse (Zhang et al., 2008), there were 31.57% of 
genes containing promoters with putative G-quadruplex motifs in the whole 
mouse genome. When we look at the complete list of genes that were deregulated 
by RHAU-ablation (2-fold, p value < 0.05), we found that there were 83 out of 
377 genes (35.4%) containing G-quadruplex motifs at their promoters.  There was 
no obvious enrichment of gene in numbers. However, when we group the genes 
according to their functions and localization, the result was interesting. We found 
that there were around 42% and 50% of the genes which involved in cell death 
pathway and cell cycle regulation, respectively, were containing putative G-
quadruplex motifs in their promoters (Table 3.3B).  
 
On another hand, there were 24 out of 377 genes (6.3%) that are deregulated by 
RHAU knockout are containing G-quadruplex motifs in their RNAs (Kikin et al., 
2008). Amongst them, 8% (11/136) of genes were downregulated and 5.4% 
(13/241) of genes were upregulated.  
 
In mouse genome, there is at least ~5% of genes contain ARE in the 3’UTR. 
Amongst the genes that were deregulated by RHAU knockout, there were 8 out of 
377 genes contain ARE in their 3’UTR. Amongst these genes, 3 out of 136 (2%) 
were downregulated, and 5 out of 241 (2%) were upregulated. Therefore, in the 
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RHAU knockout ProEs, there were no obvious enrichement of gene in numbers 
that contain ARE in the 3’UTR of mRNA (Halees et al., 2008).  
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Genes associate with cell death pathway
 Extracellular Space
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10364535 -3.730  ELA2  elastase, neutrophil expressed  peptidase    
 10364529 -2.960  PRTN3  proteinase 3  peptidase yes   
 10481627 -1.583  LCN2  lipocalin 2  transporter yes   
 10452316 -1.550  C3  complement component 3  peptidase    
 10408693 -1.429  F13A1  coagulation factor XIII, A1 polypeptide  enzyme yes   
 10389214 -1.237  CCL9  chemokine (C-C motif) ligand 9  cytokine yes yes  
 10478633 -1.219  MMP9
 matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase)
 peptidase yes  yes
10415052 -1.031  MMP14  matrix metallopeptidase 14 (membrane-inserted)  peptidase    
10563116 1.006  FLT3LG  fms-related tyrosine kinase 3 ligand  cytokine    
 10373912 1.068  OSM  oncostatin M  cytokine yes  yes
 10425161 1.184  LGALS1  lectin, galactoside-binding, soluble, 1  other yes yes  
 10569962 1.839  CCL25  chemokine (C-C motif) ligand 25  cytokine    
12 0.666666667   
 Plasma Membrane   
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10478048 -1.731  LBP  lipopolysaccharide binding protein  transporter yes   
10550509 -1.561  PGLYRP1  peptidoglycan recognition protein 1  transmembrane receptor   
 10501608 -1.435  VCAM1  vascular cell adhesion molecule 1  other   yes
 10561008 -1.172  CEACAM1
 carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein)
 transmembrane 
receptor  yes
 10466172 -1.160  MS4A1  membrane-spanning 4-domains, subfamily A, member 1  other    
10502224 -1.126  SGMS2  sphingomyelin synthase 2  enzyme    
 10557862 -1.065  ITGAM  integrin, alpha M (complement component 3 receptor 3 subunit)  other    
 10363173 -1.033  GJA1  gap junction protein, alpha 1, 43kDa  transporter    
 10559486 -1.014  LAIR1  leukocyte-associated immunoglobulin-like receptor 1
 transmembrane 
receptor   
 10546024 1.109  PROKR1  prokineticin receptor 1  G-protein coupled receptor yes   
 10476314 1.227  PRNP  prion protein  other yes   
 10438530 1.247  CLCN2  chloride channel 2  ion channel yes   
 10497079 1.421  PTGER3 prostaglandin E receptor 3 (subtype EP3)
 G-protein coupled 
receptor  yes
 10507594 2.927  SLC2A1  solute carrier family 2 (facilitated glucose transporter), member 1  transporter yes   
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   Cytoplasm   Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10420261 -3.566  CTSG  cathepsin G  peptidase    
 10380174 -3.147  MPO  myeloperoxidase  enzyme    
 10499861 -1.988  S100A9  S100 calcium binding protein A9  other yes   
 10493831 -1.835  S100A8  S100 calcium binding protein A8  other    
 10603551 -1.565 CYBB (includes EG:1536 cytochrome b-245, beta polypeptide  enzyme    
 10597098 -1.534  CAMP  cathelicidin antimicrobial peptide  other yes   
 10411235 -1.313  IQGAP2  IQ motif containing GTPase activating protein 2  other    
 10501229 -1.292  GSTM5  glutathione S-transferase mu 5  enzyme    
 10534202 -1.268  NCF1  neutrophil cytosolic factor 1  enzyme    
 10523595 -1.263  PTPN13
 protein tyrosine phosphatase, non-
receptor type 13 (APO-1/CD95 (Fas)-
associated phosphatase)
 phosphatase   yes
10461979 -1.056  ALDH1A1  aldehyde dehydrogenase 1 family, member A1  enzyme    
 10476301 1.043  SMOX  spermine oxidase  enzyme   yes
10488655 1.220  BCL2L1  BCL2-like 1  other    
 10430956 1.280  CYB5R3  cytochrome b5 reductase 3  enzyme    
10563338 1.334  PPP1R15A (includes EG:23645)
 protein phosphatase 1, regulatory 
(inhibitor) subunit 15A  other    
 10389654 1.363  EPX  eosinophil peroxidase  enzyme   yes
 10443527 1.424  PIM1  pim-1 oncogene  kinase yes   
10469255 1.536  PRKCQ  protein kinase C, theta  kinase    
 10425410 2.133  GRAP2  GRB2-related adaptor protein 2  other    
  
Nucleus   
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10531724 -1.924  PLAC8  placenta-specific 8  other yes   
10541260 -1.286  CECR2  cat eye syndrome chromosome region, candidate 2  other    
 10366266 -1.181  PAWR  PRKC, apoptosis, WT1, regulator  transcription regulator yes   
 10473809 -1.138  SPI1  spleen focus forming virus (SFFV) proviral integration oncogene spi1
 transcription 
regulator yes   
 10542317 1.019  CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1)  other yes   
 10545921 1.244  MXD1  MAX dimerization protein 1  transcription regulator yes   
10545130 1.397  GADD45A  growth arrest and DNA-damage-inducible, alpha  other    
 10449284 1.501  DUSP1  dual specificity phosphatase 1  phosphatase yes   
 10443463 1.581  CDKN1A  cyclin-dependent kinase inhibitor 1A (p21, Cip1)  kinase    
 10404059 1.600  HIST1H1C  histone cluster 1, H1c  other    
 10476252 1.725  CDC25B cell division cycle 25 homolog B (S. pombe)  phosphatase yes   
 10505512 1.893  TRIM32  tripartite motif-containing 32  transcription regulator   
 10357875 1.973  BTG2  BTG family, member 2  transcription regulator yes yes  
 10405211 2.271  GADD45G  growth arrest and DNA-damage-inducible, gamma  other yes   
 
 
 
 
 
 
 Extracellular Space
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10478633 -1.219  MMP9
 matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase)
 peptidase Yes yes
 10563116 1.006  FLT3LG  fms-related tyrosine kinase 3 ligand  cytokine
 10373912 1.068  OSM  oncostatin M  cytokine yes yes
 10425161 1.184  LGALS1  lectin, galactoside-binding, soluble, 1  other yes yes
 Plasma Membrane
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10466224 -2.256  MS4A3
 membrane-spanning 4-domains, 
subfamily A, member 3 
(hematopoietic cell-specific)
 other
 10561008 -1.172  CEACAM1
 carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein)
 transmembrane 
receptor yes
 10363173 -1.033  GJA1  gap junction protein, alpha 1, 43kDa  transporter
 10559486 -1.014  LAIR1  leukocyte-associated immunoglobulin-like receptor 1
 transmembrane 
receptor
 10476314 1.227  PRNP  prion protein  other
 10438530 1.247  CLCN2  chloride channel 2  ion channel
 Cytoplasm
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10488655  1.220  BCL2L1  BCL2-like 1  other
 10456254  1.282  NEDD4L
 neural precursor cell expressed, 
developmentally down-regulated 4-
like
 enzyme
 10563338  1.334
 
P1R15A (includes EG:23  protein phosphatase 1, regulatory (inhibitor) subunit 15A  other
 10443527  1.424  PIM1  pim-1 oncogene  kinase yes
 10469255  1.536  PRKCQ  protein kinase C, theta  kinase
Nucleus
Probe ID logFC Gene_symbol Description Type(s) G4 promoter G4 RNA ARE
 10531724 -1.924  PLAC8  placenta-specific 8  other yes
 10366266 -1.181  PAWR  PRKC, apoptosis, WT1, regulator  transcription regulator yes
 10473809 -1.138  SPI1  spleen focus forming virus (SFFV) proviral integration oncogene spi1
 transcription 
regulator yes
 10362811 1.001  SESN1  sestrin 1  other Yes
 10542317 1.019  CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1)  other yes
 10569102 1.05  IRF7  interferon regulatory factor 7  transcription regulator yes
 10545921 1.244  MXD1  MAX dimerization protein 1  transcription regulator yes
 10545130 1.397  GADD45A  growth arrest and DNA-damage-inducible, alpha  other
 10449284 1.501  DUSP1  dual specificity phosphatase 1  phosphatase yes
 10523297 1.566  CCNG2  cyclin G2  other
 10443463 1.581  CDKN1A  cyclin-dependent kinase inhibitor 1A (p21, Cip1)  kinase
 10425207 1.678  H1F0  H1 histone family, member 0  other
 10476252 1.725  CDC25B cell division cycle 25 homolog B (S. pombe)  phosphatase yes
 10357875 1.973  BTG2  BTG family, member 2  transcription regulator yes yes
 10405211 2.271  GADD45G  growth arrest and DNA-damage-inducible, gamma  other yes
Genes associate with cell cycle regulation pathway
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Localization of the protein
No. of genes with 
putative G4-
promoter
Total no of genes Percentage of gene with 
putative G4- promoter
Extracellular Space 7 12 58.33
Plasma Membrane 5 14 35.71
Cytoplasm 3 19 15.79
Nucleus 10 14 71.43
Overall 25 59 42.37
Genes involve in cell cycle regulation
Localization of the protein
No. of genes with 
putative G4-
promoter
Total no of genes Percentage of gene with 
putative G4- promoter
Extracellular Space 3 4 75.00
Plasma Membrane 0 6 0.00
Cytoplasm 1 5 20.00
Nucleus 11 15 73.33
Overall 15 30 50.00  
 
 
 
Table 3.3 Genes deregulated in ProE when RHAU was knockout out. (A) Genes that involve in cell death 
pathway and cell cycle regulation were listed in separated table analyzed by Ingenuity Pathways Analysis 
(Ingenuity system) software. (B) Summary of gene numbers that contain putative G-quadruplex motif (G4) in 
their promoters.  
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4 DISCUSSION 
 
We suggested previously that RHAU is a multi-functional protein after showing 
that (1) it enhances urokinase mRNA decay by recruiting poly(A) ribonuclease 
and exosomes to the AU-rich element in the message (Tran et al., 2004), (2) it 
translocates to cytoplasmic stress granules upon various stresses in a manner 
dependent on its RNA binding (Chalupnikova et al., 2008) and is co-localized in 
nuclear speckles with DEAD-box helicases p68 and p72 (Iwamoto et al., 2008) 
that are involved in transcriptional regulation, (3) it influences the transcription of 
various genes both positively and negatively, as revealed by RNAi-mediated 
knockdown in HeLa cells (Iwamoto et al., 2008), and (4) it displays and is a 
major source of tetramolecular quadruplex G4-DNA and G4-RNA resolvase 
activity in HeLa cell lysates (Vaughn et al., 2005) (Creacy et al., 2008), which 
depends on a evolution conserved RHAU-specific-motif (RSM) domain 
(Lattmann et al., 2010), in an ATP-dependent manner. Though there were 
biochemistry assays showing the interesting properties of RHAU, biological 
information is still missing. Here, we show the first RHAU knockout animal 
model which revealed RHAU is essential for embryogenesis and hematopoiesis.   
 
 
4.1 RHAU is required for mouse early embryogenesis 
 
During embryogenesis, embryo implantation occurs at 4.5 dpc and gastrulation 
starts at around 6 dpc. During gastrulation, three embryonic germ layers are 
formed by massive cell migration accompanied by a burst of the transcription of 
key genes important for organogenesis (Pfister et al., 2007; Tam and Loebel, 
2007). We found that RHAU knockout embryos degenerated before 7.5 dpc. 
RHAU appears to become indispensable for gastrulation. We also found that there 
was no difference in embryo implantation rates between two different breeding: 
RHAUΔ/+ × RHAUΔ/+ and RHAU+/+ × RHAUΔ/+, the former of which should give 
rise to embryos of RHAUΔ/Δ genotype. This resuts suggests that RHAU ablation 
does not affect implantation. However, we cannot exclude the possibility that 
other helicases compensate the loss of RHAU at this stage. Interestingly, embryos 
with the ablation of DHX9, another DEAH helicase, knockout embryos also 
degenerated at similar time point during gastrulation. It would be interesting to 
understand why DEAH helicase be important for gastrulation (Lee et al., 1998).  
  
4.2 RNA helicases in hematopoiesis 
 
Haematopoiesis involves qualitatively asymmetric cell divisions followed by 
propagation to establish progenitor cells at several steps. The asymmetric cell 
division should involve alteration of gene expression, whether its regulation is at 
the step of template DNA modification, transcription, mRNA maturation or 
translation, in some of which RNA molecules are necessarily engaged. Thus, the 
involvement of specific RNA helicases in this process is expected. However, so 
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far only one member of the DEAH RNA helicase family has been suggested to 
play a role in the hematopoiesis. It was found that ubiquitously expressed DHX32 
was specifically down-regulated in acute lymphoblastic leukemia (Abdelhaleem, 
2002), possibly through suppressing apoptosis (Alli et al., 2007). Causal role of 
this helicase in leukemia development, however, has not yet been addressed. In 
the present work by ablating RHAU specifically in the hematopoietic system, we 
have shown an essential role of RHAU in the hematopoiesis acting in a stage- and 
lineage-specific manner. As the hematopoiesis involves many discrete steps in 
which various RNA molecules should be modified both covalently and non-
covalently, it would not be surprising to find in future more RNA helicases 
playing important roles in the process. The application of the same strategy 
employed in this work to other RNA helicases may unravel interesting roles of 
them in the hematopoiesis and the potential therapeutic target for hematopoietic 
system disorder.   
 
 
4.3 Loss of RHAU causes anemia, low blood platelet counts and 
leucopenia  
 
Complete blood counting consistently showed  decrease of RBC, PLT and WBC 
cells in RHAU ablated conditions brought about by different systems: (1) 
RHAUfl/fl; iCretg mice, (2) recipient mice transplanted with RHAUfl/fl; iCretg bone 
marrow, and (3) recipient mice transplanted with RHAUfl/fl; MxCretg bone 
marrow and treated with polyI:C treatments (Table 3.2). The effects of RHAU 
knockout on low red blood cell counts, low blood platelet counts and leucopenia 
were cell autonomous. RHAU-ablation mice developed anemia and 
reticulocytosis. Increased MCV was due to increased reticulocytes counts because 
reticulocytes are generally larger than mature red blood cells. Erythrocytosis is 
promoted by Epo signaling. It is common amongst mammals that anemia induces 
Epo production in order to compensate the anemic condition. In fact, we also 
found that the plasma Epo was 800 times higher in the RHAUfl/fl; iCretg mice than 
the control RHAUfl/fl mice (Figure 3.11). Therefore, reticulocytosis was not 
directly due to RHAU-ablation. A more detailed discussion on anemia in 
RHAUfl/fl; iCretg mice will be presented later (see below).  
 
Amongst the WBC, the neutrophil and lymphocytes were decreased in number in 
the RHAU-ablated mice of all groups. However, basophils and esinophils counts 
were not affected by RHAU-ablation in mice that received bone marrow 
transplantation but increased in number in RHAUfl/fl; iCretg mice (which did not 
receive bone marrow transplantation). We do not know what causes the 
discrepancy of basophils and esinophils counts between the two systems. One 
possible cause of this discrepancy is the different housing environment of the two 
groups of mice. The RHAUfl/fl; iCretg mice and their control siblings were housed 
in open cages while the recipient mice were housed in sterilized filter-top cages. 
An increase in number of basophils and esinophils in the RHAUfl/fl; iCretg mice 
might be the consequence of exposure to air borne pathogens.  
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Since RHAU-ablation in mice with the vav-iCre system or in recipient mice that 
received RHAU-ablated bone marrow cells showed similar phenotypes in the 
peripheral blood, it is suggested that the observation obtained in mice with the 
vav-iCre system was not caused by non-specific Cre activity in non-
hematopoietic systems. Therefore, we decided to study the effect of RHAU 
ablation in hematopoiesis in a more detail manner using this RHAUfl/fl;iCretg mice.  
 
  
RHAU ablation specifically in the hematopoietic system causes a defect in 
hematopoiesis  in the bone marrow and extramedullary hematopoiesis 
 
We found that there was a reduction in bone marrow cellularity in RHAUfl/fl; 
iCretg because the number of cells recovered from RHAUfl/fl; iCretg mice was 
always lower than that from control sibling mice. Morphological examination by 
hematoxylin and eosin staining revealed thickening of femur and tibia bones in 
RHAUfl/fl; iCretg mice. At the same time, the spleen of RHAUfl/fl; iCretg mice was 
enlarged. Though the RHAU-ablated mice were anemic, complete blood count 
showed the RHAUfl/fl; iCretg mice developed reticulocytosis induced by high 
serum Epo level, In vitro colony forming assay showed BFU-E decreased in bone 
marrow but increased in the spleen of RHAUfl/fl; iCretg mice. Parallel to the in 
vitro studies, FACS analysis showed no change of MEP and decreased of total 
erythroblast counts in the bone marrow of RHAUfl/fl; iCretg mice. However, MEP 
and total erythroblast counts increased in the spleen of RHAUfl/fl; iCretg mice. 
Therefore, the spleen became a major source of erythroblasts in RHAUfl/fl; iCretg 
mice.  
 
 
4.4 Lineage-specific effect of RHAU ablation on lymphoid cell 
differentiation 
 
RHAU appears to play an essential but differential role in the development of 
myeloid and lymphoid lineages. In the myeloid lineage, RHAU ablation hinders 
progression of erythroblast cells at the ProE-to-Ery.A stage. RHAU-ablated 
erythroblasts, however, still develop to mature red blood cells. In the lymphoid 
lineage, CLPs can develop into T cells, B cells or natural killer cells. In RHAUfl/fl; 
iCretg mice, the number of CLPs increased in bone marrow but not in the spleen. 
In these mice, however, the number of CD19+ cells was very low both in bone 
marrow and spleen. Expression of CD19 begins in ProB cells, the earliest stage in 
the B lymphoid lineage (Cobaleda and Sanchez-Garcia, 2009). This indicates that 
RHAU ablation blocks the CLP-to-B cell branch of lymphoid cell differentiation 
in the bone marrow. On the other hand, while the differentiation process of the T 
cell lineage was not completely arrested, ISP8 cells accumulated in the thymus of 
RHAU-ablated mice. Thus, in both B and T cell lineages, RHAU ablation caused 
developmental defects at stages during which DNA rearrangements occurred. In 
the B cell lineage, DH–JH rearrangements are initiated at a low level at the 
earliest lymphoid progenitor stage and are completed as the cells progress to the 
CLP and pre-pro-B cell stages (Ceredig and Rolink, 2002; Fuxa and Skok, 2007). 
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In the T cell lineage, during progression from ISP8 cells to DP cells, Vα→Jα 
arrangements at the TCRα locus occur (Okamura et al., 1998) (Ceredig and 
Rolink, 2002). Thus, the accumulation of CLP and ISP8 cells in RHAU-ablated 
mice implies that RHAU might play a role in DNA rearrangements during B and 
T lymphoid cell differentiation.  
 
Dramatic decrease of B and T cells in the hematopoietic tissues may account for 
decreased counts of lymphocytes in the peripheral blood.  
 
4.5 Specific potentiation of monocytes differentiation by RHAU 
ablation 
 
According to the Akashi-Kondo-Weissman scheme of hematopoietic 
differentiation, HSCs give rise to CMPs, CMPs to more lineage-restricted GMPs, 
and finally GMPs to monocytes, neutrophils, basophils and eosinophils (Laiosa et 
al., 2006). In the colony forming assay, colonies formed reflect the state of 
differentiation of the pathway CFU-GEMM Æ CFU-GM Æ CFU-M or CFU-G. 
The result of colony forming assays suggests monocyte differentiation potential 
specifically enhanced both in the bone marrow and spleen of RHAUfl/fl; iCretg 
mice. FACS analysis also showed an increase monocyte counts but a decrease in 
neutrophil counts in the spleen. These observations suggest that RHAU ablation 
potentiates GMPs and CMPs to differentiate into monocytes.  
 
 
4.6 Study of transcriptome in RHAU knockout ProE showed 
enrichment of genes that contained putative G-quadruplex 
(G4) motifs in their promoters 
 
G4-DNA and G4-RNA are highly stable structures that are formed in guanine-
rich motifs of DNA or RNA under physiological conditions. It was previously 
reported that RHAU was the major source of G4-DNA resolvase in HeLa cells. 
Depletion of RHAU protein either by a monoclonal antibody or shRNA 
dramatically reduced G4-DNA and G4-RNA resolving activities in these cells 
(Creacy et al., 2008; Vaughn et al., 2005). Interestingly, we observed among 
deregulated genes in ProE cells an increased number of genes that harbored G4 
motifs at their promoters and were involved in cell death and cell cycle regulation. 
This enrichment of genes with G4-DNA motif at the promoter can be detected 
only when genes are categorized according to their functions. Otherwise, there 
was no observable enrichment. In addition, the genes that code for nuclear 
proteins occupy the highest fraction of these selected genes. According to the 
biochemical feature of RHAU, it may resolve G4-DNA in vivo. G4-DNA motifs 
in the promoter are expected to be inhibitory for transcription and, if so, resolving 
this stable structure would derepress transcription. However, amongst the genes 
with G4 motifs in their promoters, not all genes were up-regulated when RHAU 
was ablated. Among deregulated genes that were involved in cell death, eleven 
genes were downregulated and thirteen genes were upregulated. Among the genes 
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that were involved in cell cycle regulation, four genes were downregulated and 
eleven genes were upregulated. Thus, RHAU ablation preferentially affects some 
genes of specific functions. We do not know yet whether RHAU directly binds 
G4 motifs of these genes in vivo. This question should be addressed by chromatin 
immunoprecipitation experiments in the future.  
 
 
Though RHAU was originally identified as a protein associating with the ARE in 
the 3’UTR of urokinase mRNA and decreasing its stabilty, we found no 
enrichment of ARE-containing mRNAs among deregulated genes in RHAU-
ablated ProEs. It may be possible that RHAU specifically regulate the stability of 
uPA mRNA or of limited number of mRNAs through AREs in the 3’UTR of 
these mRNA. It would be interesting to search for the genes that can be bound by 
RHAU and associated with the mouse phenotypes induced by RHAU ablation.  
 
 
4.7 Hemolytic anemia in RHAUfl/fl; iCretg mice 
 
One of prominent phenotypes exhibited in RHAUfl/fl; iCretg mice are anemia. 
RHAUfl/fl; iCretg pups were born with the appearance of less redness compared to 
normal pups. By complete blood counting, we found that the RHAUfl/fl; iCretg 
mice developed reticulocytosis. Although we already showed that there was a 
defect in erythropoiesis at the ProE to Ery.A step in the bone marrow and spleen, 
reticulocytes ratios were higher in  RHAUfl/fl; iCretg mice than RHAUfl/fl mice and 
serum Epo levels were enhanced in  RHAUfl/fl; iCretg mice. These results suggest 
that  the anemic phenotype of RHAUfl/fl; iCretg  mice is due to decreased life span 
of erythrocytes rather than the insufficient supply of of newly maturated 
erythrocytes from from hematopoietic organs.  
 
Blood smear examination showed the presence of spherocytes in the blood of 
RHAUfl/fl; iCretg mice. In addition, the color of the liver and kidney of these mice 
were jaundice. This is a sign of hemolytic anemia. The spherocytes observed were 
erythrocytes that lose the biconcave disk shape and had smaller diameters. 
Spherocytes are derived from erythrocytes through partially phagocytoization by 
macrophages in the reticuloendothelial system in liver, spleen and bone marrow 
(Jain, 1993). The function of the reticuloendothelial system is to filter for antigens 
and aged erythrocytes with externalized phosphatidylserine (PS) and removes 
them by phagocytosis. When the destruction rate is higher than production rate of 
erythrocytes, hemolytic anemia is resulted. There are two types of hemolytic 
anemia, immunologically-mediated hemolytic anemias and hereditary 
spherocytosis. Immunologically-mediate hemolytic anemia is induced when 
erythrocytes bound by complements or autoantibodies and recognized by 
macrophages for phgocytosis. Hereditary spherocytosis is resulted from genetic 
defects of proteins involved in cytoskeletal structure (Salomao et al., 2008) 
(Webb, 2005). Deficiency of any cytoskeletal protein leads to decrease of 
deformability and special cell shape that can be recognized by macrophages in the 
reticuloendothelial system. Spherocytes of hemolytic anemias suffer enhanced 
osmotic fragility. In order to test the osmotic fragility of erythrocytes, blood 
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samples were put in solutions of various NaCl concentraions  ranging from 0% to 
0.9% w/v. Erythrocytes are very stable in isotonic  0.9% NaCl solution. In 
solution below this concentration of NaCl, erythrocytes take up water by osmosis 
and burst. We expected that sphere-shaped erythrocytes would have less capacity 
to take up water and be prone to burst in less hypotonic solution than disc-shaped 
control erythrocytes. Surprisingly, against our expectation, the sphere-shaped 
erythrocytes were more resistance to osmotic shock than control erythrocytes. In 
order to explain this phenomenon, we examined levels of several mRNAs 
encoding membrane proteins of ProE cells.  Interestingly, we found that the 
mRNAs encoding five membrane proteins were up-regulated in RHAUfl/fl; iCretg 
mice. It was reported that lack of any of these proteins would lead to abnormal 
cytoskeleton structure in erythrocytes and causes spherocytosis (Salomao et al., 
2008) (Webb, 2005). However, in the erythrocytes of RHAUfl/fl; iCretg mice, these 
proteins were overexpressed (Table 4.1 and Figure 4.1). So, the spherical shape of 
erythrocytes might be induced not only by downregulation but also by 
overexpression of these membrane proteins. However, sensitivity to osmotic 
stress may be different between the two cases. We still do not have an answer to 
the question why the half lives of erythrocytes were shorter in RHAU-ablated 
mice.  
 
To know whether the abnormal protein arrangement in the cytoskeleton of 
erythrocytes was solely responsible for their shorter half lives in RHAU-ablated 
mice, in other words whether their shorter half lives were cell autonomous, we 
performed transfusion experiments. Blood cells of RHAUfl/fl; iCretg were biotin-
labeled in vitro and then transfused to either RHAUfl/fl; iCretg mice or RHAUfl/fl 
mice (see Figure 3.12). When transfused into RHAUfl/fl mice, the half lives of 
erythrocytes were similarly long irrespective of whether labeled erythrocytes 
were originally derived from RHAUfl/fl or RHAUfl/fl; iCretg mice. On the other 
hand, erythrocytes from RHAUfl/fl; iCretg mice showed significantly shorter half 
lives when they were transfused into RHAUfl/fl; iCretg mice than when they were 
transfused into RHAUfl/fl mice. These results clearly indicate that the shortened 
half lives of RHAUfl/fl; iCretg erythrocytes were due to an “extrinsic” effect. 
However, this “extrinsic” effect still is within the hematopoietic system as we still 
see anemic effect in the bone marrow transplantation models. Whether the 
“extrinsic” effects reflect immunological response of erythrocytes or activated 
macrophages in the reticuloendothelial system needs to be further investigated.    
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Figure 4.1. Schematic representation of two types of multiprotein complexes in the red cell membrane. (Left) 
Protein complex attached to spectrin near the center of the tetramer (dimer–dimer interaction site). 
Tetrameric band 3 is bound to ankyrin, which is bound to spectrin. The membrane skeletal protein 4.2 has 
binding sites for band 3 and for ankyrin. Transmembrane glycoproteins GPA, Rh, and RhAG bind to band 3, 
and CD47 and LWassociate with Rh/RhAG. The two cytoplasmic domains of band3 contain binding sites for 
soluble proteins, the short C-terminal domain for CAII, the large N-terminal domain for deoxyhemoglobin 
and for glycolytic enzymes, aldolase, phosphofructokinase (PFK), and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). (Right) Protein complex at membrane skeletal junctions. The junctions contain the 
ternary complex of spectrin, F-actin, and 4.1R, actin-binding proteins tropomyosin, tropomodulin, 
adducin,anddematin. 4.1R enters into an additional ternary interaction with the transmembrane protein GPC 
and p55 and is taken also to bind to band 3, in the form of a dimer, which also carries GPA. Rh, Kell, and XK 
also have binding sites on 4.1R. Note, however, that the copy numbers of all transmembrane proteins except 
GPA and GPC are low and therefore will not be present on all complexes (This figure is adopted from 
Salmona et al., 2008). The highlighted proteins were deregulated in RHAU-ablated ProE transcriptome.  
 
 
Table 4.1 Fold changes of mRNA expression in RHAUfl/fl; iCretg mice compare to control RHAUfl/fl mice 
analyzed from microarray data.    
 
Genes Fold changes
erythrocytes protein band 4.2 2.21
Band 3 3.71
Duffy 2.07
hemoglobin alpha,adult chain 1/2 2.25
tropomodulin 1 5.09
 
 
4.8 Potential target against leukemia  
 
FACS analysis showed that the number of CD19+ or B220+ B cells in bone 
marrow and spleen was drastically reduced in RHAU-ablated mice. As for T cell 
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differentiation, RHAU ablation retarded progression from ISP8 to DP cells. The 
fact that RHAU ablation suppresses lymphoid cell differentiation at relatively 
early stages suggests RHAU as a target for therapy of acute lymphocytic 
leukemia in which a transforming mutation occurs at an early stage of 
differentiation (Bernt and Armstrong, 2009) (Passegue et al., 2003). As global 
gene expression analysis showed extremely high expression of RHAU in mature 
B and T cells (Su et al., 2004), a role for RHAU in the survival of these cells 
cannot be excluded. The indispensability of RHAU at an early stage of 
differentiation may have concealed its requirement in mature B and T cells. If this 
is the case, RHAU could also be an interesting target in chronic lymphocytic 
leukemia.  
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Supplementary Table 1.Staining and enrichment procedures for different population were achieved by 
different combination of specific markers as reported previously (Forsberg et al., 2006)  (Akashi et al., 2000) 
(Christensen and Weissman, 2001; Nakorn et al., 2003). Except for MEP, CMP and GMP analysis, non-
antigen-specific binding of immunoglobulins to the Fcγwere firstly blocked with anti- Fcγ (CD16/32) 
[2.4G2] (BD Pharmingen) before the addition of other antibodies. Antibodies for different markers were 
showed in the table with the clone identity enclosed with [ ]. The suppliers of the antibodies were indicated 
for once only when it was firstly mentioned. 
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Abbreviation 
 
Baso basophils 
CMP common myeloid progenitor    
DC dendritic cell     
DN double negative     
DP double positive     
dpc days postcoitus     
Eosino eosinophils      
Ery. erythroblast      
ETP early T cell precursors   
G4 G-quadruplex      
HB hemoglobin      
Hct hematocrit      
HSC haematopoietic stem cell    
ISP immature single positive    
LMPP lymphoid primed multipotent progenitor   
LT-HSC long-term repopulating haematopoietic stem cell  
Luc large unstained cells    
Lympho lymphocytes      
MCH mean corpuscular hemoglobin    
MCHC mean corpuscular hemoglobin concentration   
MCV mean corpuscular volume    
MEP megakaryocyte/erythroid progenitor     
Mono monocytes      
MPP multipotent progenitor     
MPV mean platelet volume    
Neutro neutrophils      
NK cell natural killer cell   
ProE proerythroblast      
RBC red blood cell count   
RDW red blood cell distribution width  
RET reticulocyte count     
RNP ribonucleoprotein      
SP single positive     
ST-HSC short-term repopulating haematopoietic stem cell  
WBC white blood cell count   
WHD winged-helix domain     
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